var title_f28_62_29664="Biceps tendon rupture2";
var content_f28_62_29664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biceps tendon rupture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient shows the classic \"Popeye\" deformity associated with biceps tendon rupture. Note the gap between the contracted biceps muscle and the deltoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD, and Bryan Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29664=[""].join("\n");
var outline_f28_62_29664=null;
var title_f28_62_29665="Patient information: Kyphosis in adults (The Basics)";
var content_f28_62_29665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83448\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/19/32048\">",
"         Kyphosis caused by osteoporosis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/58/35746\">",
"         Patient information: Osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Kyphosis in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/kyphosis-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H113224871\">",
"      <span class=\"h1\">",
"       What is kyphosis in adults?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Kyphosis is the term doctors use to describe a curving of the upper back. A normal backbone (spine) has a slight curve. In a person with kyphosis, the upper part of the spine curves more than normal, causing a rounded or hunched back (",
"      <a class=\"graphic graphic_figure graphicRef83274 \" href=\"UTD.htm?31/19/32048\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Kyphosis is also called &ldquo;hyperkyphosis&rdquo; or &ldquo;dowager&rsquo;s hump.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113224886\">",
"      <span class=\"h1\">",
"       What causes kyphosis in adults?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Kyphosis in adults happens because of problems with different parts of the spine (see Kyphosis PI). These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Vertebrae &ndash; These are the bones of the spine that sit on top of one another like a stack of coins.",
"       </li>",
"       <li>",
"        Discs &ndash; These are the rubbery cushions between each of the vertebrae.",
"       </li>",
"       <li>",
"        Muscle, tendons, and ligaments &ndash; Together, these are known as the &ldquo;soft tissues&rdquo; of the back. These tissues support the back and help hold it together.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The problems that can cause kyphosis include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Osteoporosis &ndash; This disease causes weak bones that break too easily. Tiny cracks or breaks in the vertebrae (called &ldquo;vertebral fractures&rdquo;) can cause the vertebrae to collapse or shrink.",
"       </li>",
"       <li>",
"        Degenerative disc disease &ndash; This happens when the spinal discs start to shrink and break down.",
"       </li>",
"       <li>",
"        Weak muscles in the lower back &ndash; Weak back muscles can make it hard to stand up straight. This can cause slouching.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113224903\">",
"      <span class=\"h1\">",
"       What are the symptoms of kyphosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is a hunched or rounded back that might hurt or feel stiff. People with kyphosis might also notice that their belly has gotten bigger even though they have not gained weight. Other possible symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Neck or hip pain",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Trouble swallowing",
"       </li>",
"       <li>",
"        Having acid that is normally in your stomach back up into your throat (a condition called &ldquo;acid reflux&rdquo;)",
"       </li>",
"       <li>",
"        Having a hard time doing everyday things, like walking, getting up from a chair, dressing, and bathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113224918\">",
"      <span class=\"h1\">",
"       Is there a test for kyphosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse should be able to tell if you have it by doing an exam. But you will likely get a back X-ray and other tests to measure the curve of your back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113224933\">",
"      <span class=\"h1\">",
"       How is kyphosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on what caused the problem and how serious it is. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines for osteoporosis",
"       </li>",
"       <li>",
"        Exercises to stretch and strengthen the back",
"       </li>",
"       <li>",
"        Medicines to ease pain",
"       </li>",
"       <li>",
"        Surgery &ndash; Doctors do surgery only if a person has trouble breathing or has very bad pain that does not get better with medicines or other treatments.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113224948\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       Patient information: Osteoporosis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/62/29665?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83448 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29665=[""].join("\n");
var outline_f28_62_29665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113224871\">",
"      What is kyphosis in adults?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113224886\">",
"      What causes kyphosis in adults?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113224903\">",
"      What are the symptoms of kyphosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113224918\">",
"      Is there a test for kyphosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113224933\">",
"      How is kyphosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113224948\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/19/32048\">",
"      Kyphosis caused by osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_62_29666="Other spore characteristics";
var content_f28_62_29666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Other spore characteristics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Burge HA, Burge W, Muilenberg ML, Pan PM and Solomon WR. Airborne pollen and fungus spore identification: Hands On Workshop, Postgraduate Course, University of Michigan Medical School, Ann Arbor, MI, May 1990.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29666=[""].join("\n");
var outline_f28_62_29666=null;
var title_f28_62_29667="Corner fracture";
var content_f28_62_29667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corner fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagrammatic representation of a corner fracture through the subphyseal region of the metaphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29667=[""].join("\n");
var outline_f28_62_29667=null;
var title_f28_62_29668="Febuxostat: Drug information";
var content_f28_62_29668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Febuxostat: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/21/20820?source=see_link\">",
"    see \"Febuxostat: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7254933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Uloric&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11508520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Uloric&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7258706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antigout Agent;",
"     </li>",
"     <li>",
"      Xanthine Oxidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7258764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Management of hyperuricemia in patients with gout:  Note:",
"     </b>",
"     It is recommended to take an NSAID or colchicine with initiation of therapy and may continue for up to 6 months to help prevent gout flares. If a gout flare occurs, febuxostat does not need to be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling: Initial: 40 mg once daily; may increase to 80 mg once daily in patients who do not achieve a serum uric acid level &lt;6 mg/dL after 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling: 80 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7258765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7258766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-89 mL/minute): No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Insufficient data; use caution (use not recommended in the Canadian labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not studied (use not recommended in the Canadian labeling)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7258767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh class C): Not studied; use caution (use not recommended in the Canadian labeling)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7258774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uloric&reg;: 40 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7258704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7258769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without meals or antacids.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7258707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic management of hyperuricemia in patients with gout",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7258745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Liver function abnormalities (5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Aggression, agitation, alkaline phosphatase increased, alopecia, amylase increased, anaphylactic reaction, anaphylaxis, anemia, angina, angioedema, anorexia, anxiety, aPTT prolonged, atrial fibrillation/flutter, bicarbonate decreased, blurred vision, bruising, BUN increased, cardiac murmur, cerebrovascular accident, cholecystitis, cholelithiasis, constipation, CPK increased, creatinine increased, deafness, dehydration, depression, dermatitis, dermographism, diabetes mellitus, dyspepsia, dyspnea, ECG abnormal, eczema, edema, EEG abnormal, epistaxis, erectile dysfunction, flushing, gait disturbance, gastritis, gastroesophageal reflux, gingival pain, Guillain-Barr&eacute; syndrome, gynecomastia, hair color change, hair growth abnormal, hematemesis, hematochezia, hematocrit decreased, hematuria, hemiparesis, hepatic failure (fatal and nonfatal), hepatic steatosis, hepatitis, hepatomegaly, herpes zoster, hot flashes, hyperchlorhydria, hypercholesterolemia, hyperglycemia, hyperhidrosis, hyperkalemia, hyperlipidemia, hypernatremia, hypersensitivity, hyper/hypotension, hypertriglyceridemia, hypokalemia, idiopathic thrombocytopenic purpura, incontinence, influenza-like syndrome, jaundice, joint swelling, lacunar infarction, LDH increased, lethargy, leukocytosis, leukopenia, libido decreased, lymphocytopenia, MCV increased, MI, migraine, mouth ulceration, muscle spasm/twitching, myalgia, nephrolithiasis, neutropenia, pain, palpitation, pancreatitis, pancytopenia, panic attack, paresthesia, peptic ulcer, personality change, petechiae, pharyngeal edema, photosensitivity, pollakiuria, proteinuria, PSA increased, psychotic behavior, PT prolonged, renal failure, respiratory infection, rhabdomyolysis, sinus bradycardia, skin/pigmentation discoloration, splenomegaly, Stevens-Johnson syndrome, stroke, tachycardia, taste altered, thrombocytopenia, TIA, tinnitus, tremor, TSH increased, tubulointerstitial nephritis, urinary tract infection, urine output decreased/increased, urticaria, vertigo, vomiting, weakness, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7258712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent use with azathioprine or mercaptopurine",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to febuxostat or any component of the formulation; concomitant administration with theophylline",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7258713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic failure: Postmarketing cases of hepatic failure (both fatal and nonfatal) have been reported (causal relationship has not been established). In controlled studies, significant hepatic transaminase elevations (&gt;3 x ULN) have occurred (causal relationship not established). Liver function tests should be evaluated at baseline, 2 and 4 months after initiation of therapy, and periodically thereafter; evaluate liver function tests in patients experiencing signs and symptoms of hepatic injury (eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice). Interrupt therapy in patients who develop abnormal liver function tests (eg, ALT &gt;3 x ULN); permanently discontinue use if no other explanation for the abnormalities is elucidated and in patients who develop ALT &gt;3 x ULT",
"     <b>",
"      and",
"     </b>",
"     serum total bilirubin &gt;2 x ULN.  All other patients may be cautiously restarted on febuxostat.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolic events: MI, stroke and cardiovascular deaths were reported at a slightly increased rate than allopurinol in controlled studies (a causal relationship has not been established). Patients should be monitored for signs and symptoms of MI or stroke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (Child-Pugh class C); not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); insufficient data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Administer concurrently with an NSAID or colchicine (up to 6 months) to prevent gout flare upon initiation of therapy. Do not use to treat asymptomatic or secondary hyperuricemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7273306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Febuxostat may increase the serum concentration of AzaTHIOprine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Febuxostat may increase the serum concentration of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Febuxostat may increase the serum concentration of Mercaptopurine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Febuxostat may increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated.  Management: The U.S. febuxostat labeling recommends using caution in patients receiving concomitant theophylline due to risks of increased theophylline metabolite exposure. The Canadian febuxostat labeling contraindicates its use with theophylline.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7258708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7258709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated increased neonatal mortality and reduction in weight gain, but not teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit to the mother outweighs potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7258711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16354745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if febuxostat is excreted in breast milk.. The manufacturer recommends that caution be exercised when administering febuxostat to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7258768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with or without meals or antacids.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7679963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Uloric Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $222.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $222.71",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7258771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests at baseline, 2 and 4 months after initiation and then periodically, serum uric acid levels (as early as 2 weeks after initiation)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F7258753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uric acid, serum: An increase occurs during childhood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males: 3.4-7 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: 2.4-6 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target: &lt;6 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Values &gt;7 mg/dL are sometimes arbitrarily regarded as hyperuricemia, but there is no sharp line between normals on the one hand, and the serum uric acid of those with clinical gout. Normal ranges cannot be adjusted for purine ingestion, but high purine diet increases uric acid. Uric acid may be increased with body size, exercise, and stress.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adenuric (BE, CZ, DE, EE, FR, GB, IE, NL, PT, SE);",
"     </li>",
"     <li>",
"      Atenurix (PH);",
"     </li>",
"     <li>",
"      Fabuzest (IN);",
"     </li>",
"     <li>",
"      Feburic (HK, JP, KP);",
"     </li>",
"     <li>",
"      Febuxtat (AR);",
"     </li>",
"     <li>",
"      Zurig (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7258751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid thereby decreasing uric acid. At therapeutic concentration does not inhibit other enzymes involved in purine and pyrimidine synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7258754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: &ge;49%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : ~50 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~99%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive conjugation via uridine diphosphate glucuronosyltransferases (UGTs) 1A1, 1A3, 1A9, and 2B7 and oxidation via cytochrome P450 (CYP) 1A2, 2C8, and 2C9 as well as non-P450 enzymes. Oxidation leads to formation of active metabolites (67M-1, 67M-2, 67M-4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~49% mostly as metabolites, 3% as unchanged drug); feces (~45% mostly as metabolites, 12% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bruce SP, &ldquo;Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout,&rdquo;",
"      <i>",
"       Ann Pharmacother,",
"      </i>",
"      2006, 40(12):2187-94.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9079 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29668=[""].join("\n");
var outline_f28_62_29668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7254933\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11508520\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258706\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258764\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258765\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258766\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258767\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258774\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258704\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258769\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258707\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258745\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258713\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299314\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7273306\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258709\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258711\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16354745\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258768\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7679963\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258771\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258753\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390221\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258751\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258754\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9079|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/21/20820?source=related_link\">",
"      Febuxostat: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_62_29669="Normal impulse conduction";
var content_f28_62_29669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57781%7ECARD%2F58689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57781%7ECARD%2F58689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Schema of normal impulse conduction in the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAiYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuI+IHiPUNDvLSOwaMLJGWbem7nNcp/wn+uf89Lf/v0K554mEJcrPXw2SYnE01Vhaz8/+AexUV47/wAJ/rn/AD0t/wDv0KP+E/1z/npb/wDfoVP1ymb/AOruL7r7/wDgHsVFeR2XjvWpryCN3g2vIqnEQ6E165WtKrGrflPPxuX1cE0qttewUUUVqcIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVXU72LT7OS4myQuAqKMs7E4CgdyTgCk2krsaTbshmp6lb6ciGYs8shxFDGN0kh9FH9eg74rP8rVb8bru6FhE3PkWoBkA9GkOef8AdA+pp+kWLxGS8vgjajccysOQg7Rqf7o/U5PetKvLq4iVR6aI392GkdX3/wAjLGgadj5oZHbuzzOzH6knJqCeCfQ0a606SWWzT5prN2L4Xu0ZJyCBk7eQegANbdIQGBBAIPUGsIycXeO41Vl9p3RNFIksSSRsGjdQysO4PSn1z2nw6zYWNvaRtYSRwII0Z9+4qBgZ98VY8zW/TTf/AB+vSWMp21IdHXRo2aKxvM1v003/AMfo8zW/TTf/AB+j63TF7J90bNFY3ma36ab/AOP0eZrfppv/AI/R9bph7J90bNFY3ma36ab/AOP0eZrfppv/AI/R9bph7J90bNFY3ma36ab/AOP0ye51qGCSVl04hFLEDfzgZp/W6Y1Rbdk0blFeX/8ACy7z/oH2/wD32aP+Fl3n/QPt/wDvs0/rVPuel/YON/l/FHqFFeX/APCy7z/oH2//AH2aP+Fl3n/QPt/++zR9ap9w/sHG/wAv4o9Qory//hZd5/0D7f8A77NH/Cy7z/oH2/8A32aPrVPuH9g43+X8UHxd/wCQjp//AFyb+deezzRQIHmdY1LKgLHHzMwVR9SSB+Nb/inxDL4huIJZoEhMSlQEJOcnPeuO8SwT3GmKtrC08qXVtN5alQSqTo7Y3EDOFPU159WSnUbWzPrsDSqYbBxhJe9FPT7y/c3UFqYftM0cRmkEUe9sb3PRR6ng0S3UEVzBbyTRpPOGMUbNhn28nA74yK5nXtN1PXpg0cQsEt4GMP2lVkJmLAhhsfgrsHJz9/pTNQ03V77Uf7VEUcMtt5BgtnAZ22/NIFcPtXdvZOQfu56c1KgurNpV6ib5YO2lvTr/AMDudzpn/IStP+uqfzFfQtfPWmf8hK0/66p/MV9C12YLZnznE/xU/n+gUUUV3HywUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWJfH7Z4htrfrFZIbmT/ro2VQflvP5Vt1h6NhrzV3Y5mN4VbPUAIm0f984P41yYyVoW7mtLS8vIzvHCatJbWCaMzsPtG65t4bhYJ54gjfLG7DAIbYTyuQD8w78Jr/jO/t9C0qLQJdZkvLd7u6u0ntftM7LbSFGtnMSso3OQgkzghD82cmvU9V0rTtXgWDVrC0voVYOsdzCsqhh0IDA8+9OstNsbAr9hsra2KxLCvkxKmI1JKoMD7oLMQOgyfWuCMklqhHlHjbxnqmmp4w1Sw1EnR00ofZWCLi2ne2aSCYEjozDbg5yzp717FWBqtt4Z0nSXt9TtNKt9OuES3eGSBBHIijCoVxggAYAxgCmf8Jt4b/6C9r+Z/wrVUalWN6cG15IxqYilSdqk0n5tI6Kiud/4Tbw3/0F7X8z/hR/wm3hv/oL2v5n/Cj6piP+fb+5kfXcP/z8j96Oiornf+E28N/9Be1/M/4Uf8Jt4b/6C9r+Z/wo+qYj/n2/uYfXcP8A8/I/ejoq5bxT4s/sPXNJsVtPPiuWDXc2/H2WNpEiRiMc5kkX0+VXOflqf/hNvDf/AEF7X8z/AIVzGvR+ANfudSudWv7S5uby2W1WaQKz2qKGwYWK5RsuzZ65x6AVUcJWvrTl9zD67h/+fkfvRs/8J1bwvrP27Tr+GLT9QTT1kij87z3cR7dqr82SZBxg8YOecB03je3trXUbm5tJlitLpLZkLxxPHutop/3nmsihgJcYDHp65Axnm8Ivc3EreJZSk99BqLw7k2efF5eGHybvm8pcjOOuMVPBYeGtb8RyXmk67cLqst017m3aNipMEUDKA6MANsKHP3gc4IBxTeGqRV5QaXoxxxdCT5YzTfqjd8NeJY9f1S6Sz2PpwsbO9tpgCGkWcSEEg+yL+Zrb1L/kHXX/AFyf+RrI8K+FbHw1HGlhLcyBLG108ecyn93bqyoeAPmIY57egFa+pf8AIOuv+uT/AMjXNK19Drp/EjwGiiioP1AKKKKACiiigAooooAKKktbeW6uEgt0MkshwqjqTWv/AMIrrn/QNuPyFUoyeyMp16dN2nJL1Zm6Z/yErT/rqn8xX0LXiVh4X1qO+tnfTpwqyKSSBwM17bXfg4uKd0fJcR1adSVPkknvs79gooortPmgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsa/s7yDUGv9MWOUyIFnt5H2B8fdZTg4YDI54Ix0xWzRUVKaqLlkVCbi7ow11WTH7zStSR+6+UGx+IJBoF3qtx/wAemleSp/jvJgn47U3H88VuUVzLBR6tmntV0j+Z5j8VNKFt4MnuruT7TqEk0YeYjAUZ+4g/hX9T1JNfL2n6rejR555pbjeulfaiJtgLvtzvjI/h9c9MrxX1p8af+RHl/wCu8f8AOvnZrK1eJImtoGjRDGqGMYVSMFQOwxxj0r6vKqP+zpQdrN/ofD5/iIrGP2ivdR/C5mpqc76hCoWIW8l09rtIO8FUdt2c45KdMdDnNZNvquopodmDLEZ5LW2mWUqSfmdVbdnqTnOeOp+tb/8AZMB1QX7FmmUllG1Bg7SuchQx4J6k9fpieS1tEtyHt4BCkflkFBgRj+HHp7V6Tp1Hdt23/Q8RVqMWko32/C//AAPUi1G6ktbOIgp9pkZY1AQsGY9gMj0PUj61lWOq3t1dQEiONPJnMsRGctHLsyCCcdPUjnv1qlqHiCGSL7NBYwPargKsy5XA6fL0FJYa5Z5iS7063RYySjRRjCEnJIHbJ5OK5JY+jKpZT0+Z6UMnxMKPM6V38r2t2/TcutrN3HDaXE8cQM1q84jRiVxuhAzkZz85/wDr1bm1Sc3jW0CRBvtv2UO+SAPs/m7sDqc8YzWiLe1mhTEMLxeUY1GwEeWcZUexwOPYUQ2VrAFENtBGFbzBsjAw23bu477eM+nFdqhU/m00/r5nlOrS/k11/PT7jO0nU7m6uLVbhIQtxBJKoTOVKMinJPXO/PbGO9epfBr/AJHaL/rhJ/KuBjt4YyhjhjUoCqlVA2gkEgegJAP4V33wa/5HaL/rhJ/KubHxccHUUnfR/kdGAlGWOpOKt7y/P/I9y1a/t9K0u81G9cpaWkL3EzBSxVEUsxwOTwDwKz7HVl1rQLq6jtbi2Qo4CzFDuG3IYFGZSDnsfUdq1buE3FrNCJZITIjIJI8bkyMZGQRke4NYGj+GrTw3pGrJaSSyveM9xNJIsabn8sJkLGiIOFHRRnqc1+c6WP0+n8aPHaKKKk/UAoor1zRriNNK02JpkWRraIhC2CfkHat6NH2ravY8zM8x+oRjLl5r+dv0Z5HRXtQmUqrCQbW+6d3B+lZfi0k+Hb3JP3B/MVvLB8qb5jy6HEftakafsrXaW/f5HlNFFFcJ9Obfgr/katM/66j+Rr3OvDPBX/I1aZ/11H8jXudelgvgfqfF8S/x4en6sKKKK7D5wKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDhPjT/wAiPL/13j/nXz7X0F8af+RHl/67x/zr59r6bKP93+b/AEPguJf98X+FfqFNeeytyDqkTyWjB1YrGXCHY21mUEEqGCkjI49ehdUVz9pEDtYXM1tdKMxSwuUZW9iOR6fjXdiYSnSlGO7R5WBqQpYmE6myaKMugLqrPa2lvp9xeXliLrTptPSSMTmOVlkBR8FTtEmcKB+6GOpNRavBpulWWoX2lWVtdiG/XThJKpkjRY4x+82k4zKwduem04xXLXGp6tFqwvLi+vl1KPgXDTP5q8Y4bOenvTdGu9Utbhho1zeW80g2sbaRkLD3KnpXxnK78ttT9Q54qPNfTudjoFw1zZuXt1ttsrKIlDBUHBwNxJxz3JrSqvp8MkNqouJHluGy8sjsWZnPJJJ61Yr7PDRlClGMt0j8vx1SFXEznT2bYV3Pwa/5HaL/AK4Sfyrhq7n4Nf8AI7Rf9cJP5VhmX+6VPRmuVf75S/xI9j8ZtqieFdUbQATqggb7OFALbv8AZB4LYzjPGcVg+Dfto0bWRd3d5cQY3QrdWtzE0WU+ZQ1x87jIz3Azgeg6rW9St9F0a/1S+LC0sbeS5mKjJCIpZsDucA1n2+tw6pb6vbC3ubW6tI/3kNyoVtrqSjjBI2tg98ggggEYr83TfKfqlP40eLUUUVB+oBW7ceGLrX9ecbIYLR9E0xPtktsXkRkluWIgfICuMqc87dyHHTOFXpela/pcOl2UUl4iyJBGrAg8EKAR0rswclGTuz53iKjUq04KnFvXornKQaZqa65d6WILq203R2u9QsrxYPMVpJ0PlBB0cxmS5GztiP1qbRZL5vB+tRahFegRMipPctP+/wDlXLKs6iROeo5XPQ9QOv8A+Ej0j/n9j/I/4Vm+I9c0260S7hgu0eV1AVQDzyPauypUg4PVHzmDweIjiKbdN2uuj7nnlFFFeOfopt+Cv+Rq0z/rqP5Gvc68M8Ff8jVpn/XUfyNe516WC+B+p8XxL/Hh6fqwooorsPnAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOE+NP/ACI8v/XeP+dfPtfQXxp/5EeX/rvH/Ovn2vpso/3f5v8AQ+C4l/3xf4V+oUUUV6h8+RzQRTDE0SSD/bUGliijhXbDGka+iqAKfRS5Ve9tS+eVuW+gUUUUyArufg1/yO0X/XCT+VcNXc/Br/kdov8ArhJ/KuLMv90qejPQyr/fKX+JHsXjbSp9d8Ga9pFo0aXN/p9xaxNKSEDyRsoLEAnGSM4BqO20RNLttWuXu7q+vbuP97c3OwOVRSFUBFVQBlug6sfWtyRN8bISw3AjKnBH0NcT8NbV7D4VaZZXCX0V1a6dHBcRXiOrRyrCquq7wMoCCAVyvoTX5uvhP1Sn8aPMaKRiFBLEAAZJPalqD9QCioWuIFuFt2mjFwy7ljLDcR6gdcVNTFdMKKKbkbtuRnGcUhjqKKKANvwV/wAjVpn/AF1H8jXudeGeCv8AkatM/wCuo/ka9zr0sF8D9T4viX+PD0/VhRRRXYfOBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVw3xV8Sah4b0+xm0xo1eaVkbem7gDNebf8LU8S/8APW1/78Cu6hl1WvBThax5GLzrD4Sq6VS912X/AAT0f40/8iPL/wBd4/518+11PiHxzrWv6cbHUXgaAsHISMKcjpzXLV7+Aw8sPS5J73Pjs4xtPG4j2tK9rJahRRRXaeUFFFFABXH654glecxWEhSJDguOrH/Cupvywsbkx/fEbbfrg1XslEOkeD/7VtEi069+02ss8luFAVzsWTdjkoG3Dn+GvHzbEzpqMIO1z6fhzA0q8pVaqvy7L9TjLbWb+CQMLmR+clZDuB/OvbPgHqUepeLY3QbZFhkDpnocfyrjTpzaWbzRrG1hk8SaZYRgKqLJI07yh5tgwd0iIypxkgKxHTI6P4Df2qPimRrMLw3JsGLrJEI3PTaWAAOcZ5PJ4rxHi6iozpt3TT/I+kxGXUJVIVoxSlFrbTr1Po3WdSt9H02a+vSwt4sbioyeWAHH1Iqu2pW99DrlvbljJp7m2nyMAOYUlGPUbZU/Wpte0qDW9HutOumkSG4TYXjIDoeoZcgjIIBGQRxyDVPRvD0elxasPtt3dzanP9onmudm7f5McPARVAG2JeMdc185pY9iDtJNnz94tikn8K6zFBG8ksllMiIgJZmKMAAB1NZWv3l1dyWn2H7dFZDzBOwtZ0cP8uzhQHI+/wAjIyBmvdv+Fc2n/P8Az/8AfAo/4Vzaf8/8/wD3wKcZWPs6ubYOd7Tte3R9Hf8A4c+dbvS7ueO7ubg38s2/Tnd40dPMCPGZGVBzkAMcDkH3ro/EEkq6VarbJdMkkiq8iiXfGu0ncyphzyACBg884ANez/8ACubT/n/n/wC+BR/wrm0/5/5/++BTc7kRzPBRTtN6+T7t/qfPFjHqPmwXd2NQ+1fYJoY3EUgy6yNt3DnBK7SN3Xjkmp7iLVLVLSWJ76eX7GJJZGTc4bzYSyjA67Q/yj34r6A/4Vzaf8/8/wD3wKP+Fc2n/P8Az/8AfAp+012JWY4JRt7R/czwhHv9QvUVjqEVlJfyAna8J8kQArzgFRv78c8VJ4aXUUnsGvGvG8+xL3Hn5wsoZQODwpwW4GM4zXuf/CubT/n/AJ/++BR/wrm0/wCf+f8A74FJz0tYuOaYNS5nUd/R+X9fNnH+Cv8AkatM/wCuo/ka9zrg7DwJFY3kV1bajMs0R3KTGpwa6H+ypCMtqupM/dvNUc+uAuP0xW9DEKlGzR4uc4mjjKsZ05aJW2fc26KxDY6jGD5GtXJPYTwxOv44VSR+NPsdXcXMdlq0Itbx+I2U5in/ANxvX/ZPP1611U8VCbtseO6TteLubFFFFdJkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeW/Hz/kEaV/13b/0GvFK9r+Pn/II0r/ru3/oNeEXuowWUkccolZ3R5AI4y+FXG48f7w/Ovqcsajhk35/mfn+fQlPHyUVd2X5FyiqcupWkb2atKM3f+pIGQ3AOfYcj8x60831uNRFiX/0kx+btwfu5x19fb2rv549zxvZT7Fmiit2y8Ja9fWsVzaaXcSwSDcjqBhhRKcYaydgp0p1XaEW/TUwqK6T/hB/Ev8A0Brr8h/jR/wg/iX/AKA11+Q/xqPb0v5l96NfqeI/59y+5nNkAgg9DXD61oc9tdE2sTywOcrsUsV9jXrn/CD+Jf8AoDXX5D/Gj/hB/Ev/AEBrr8h/jXLioYfExtKa080ehl9XGYCblCm2nurM8UTTL52CizuATxzGQPzNe1/s96X/AGb4tTeQ08kEhcjoOOAKP+EH8S/9Aa6/If410/w58P61oXiVL3UNJvVgETqSqAnJHHGa8yvhMPRw9SUZ8zs7bHsU8wxuLxFKnKm4x5lfR9+p6P4zivrhtDt7J7yOGbUFS7a1LKwh8qUnLLyo3BBnjkjBBxXP+Dodct9W0d72XVpY5or+K6F0XZFEc6Lbkg8KxQHDdXySS3Wuw/tVv+gbqX/fj/69H9qt/wBA3Uv+/H/16+OXMlax9p7ORp0Vmf2q3/QN1L/vx/8AXo/tVv8AoG6l/wB+P/r1PLLsHs5GnRWZ/arf9A3Uv+/H/wBej+1W/wCgbqX/AH4/+vRyy7B7ORp0Vmf2q3/QN1L/AL8f/Xo/tVv+gbqX/fj/AOvRyy7B7ORp0VlS60sMTyzWGopEgLMxg4UDqeDWnG6yRrJGwZGAZWU5BB7ik7rcTg46sdRRRSJCq2pWUOo2cltcAlG6MOGRh0ZT2IPINWaKATad0VtAuprrTh9qIN1C7QSkDAZlJG7HuAD+NaNY2hr5OpazAv3DOsw9i6LkfmpP41X0nxjomrWdldWF2ZLe8u2soX8tgDKFZsHI4BVCQTwcrg/MM+xQk5U02Kqkpu39XOhornrjxjotvqFvZzXLrLcXrafG3lNsMyhcruxgcsFz03cdatN4i01dBvtZaciwsmuEmcqRhoJHjkAB64ZGA9e3WtdiEnJ2Rr0V4X8P/j3Dr3iaDSta02Kwiun8uC4SYsFY/dVwR34GR37dx7pUQqRqK8ToxWErYSXJWVmFFFFWcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUyWWOJN8rqi+rHAoBK+w+iq/2+z/AOfq3/7+D/Gj7fZ/8/Vv/wB/B/jSui/Zy7Fiiq/2+z/5+rf/AL+D/Gj7fZ/8/Vv/AN/B/jRdB7OXYsUU1HWRAyMGU9CDkGnUyAooooAKKKKACiiigAooooAKKKKAPLfj5/yCNK/67t/6DXz9rGktqN3E5meKNLeaLdG7KwZzGQeOo+U5B9q+hvjpbT3OlaYLeGSUidiQilsfL7V43/Zd/wD8+N1/35b/AAr6fLlGWFUZf1qfBZ26kMfKcN7L8jkbrRby8UySTxW80cCRwJBgxh1bdk5XIG4JwOy9alOkXTX/ANvNwBcfaRIIgQUCAbCM7d2dpY46bj+NdT/Zd/8A8+N1/wB+W/wo/su//wCfG6/78t/hXZ7Knvf8TzPb17Wt+BTr6a+HP/Ij6N/1wH8zXzj/AGXf/wDPjdf9+W/wr6Q+H0bxeC9ISVGR1gAKsMEcntXnZw06Ubd/0Pb4ZjKOInddP1R0NFFFfOn2oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAdawjpd3ppLaLIjW/X7FcE7R/wBc35KfQgj0xW7RWdSlGorSLhNx2MH+2lgkEep2d1YuQSC6h0bHoyEjv3wav2d1b3sCzWk0c0TdGRgRV+s270SwuZjO0HlXJ6zwMYpD9WXBP0Oa45YJr4X95fPB7q39f11LVFYtzLd6HKr3c8l5pTfK0zqPMtz6ttABT3xkd8jkbVckouD5ZDlG2u6OX8SQ3vmajZadcxW1xrFo0EE0pKiKYDbkEAknaxYD1Ttmslfh/e6fp+sWWlaiJYpUtLqwa7Cq0N5b4CZEUajyysUCnAzhW65q74d8V6B48gvrCB2F1bOyzW7/ACyRlWwHU/XkEdK6PQr2aTzbG/IN/a4DsBgSofuyAe+DkdiCPSuzB1l/DfyLr0pR+JWa3/RnLL4Dln03QLO/mikFvFdHUJY2KtJPcDc8kfHB8xmYE4I4715t8ZI9X8LfBiz0fVJ4Zr/UNXuZrua1yInEk81xgAgEcunH+yevWvoivN/2gtBk174ZagIF3T2DLfIvqEBDf+OMxrqrJum0i8tlGGLpue10fGI46V9k/s/+MLjxb4IA1KXzdR0+T7NK5+9IuAUc+5GRnuVJr42r279lLWPsnjHUtLdsR31r5ij1eM5A/wC+Wf8AKvPws+Wol3Pss9wyrYSUrax1X6/gfVFFFZmqam1vOlpZQ/aL+RdwQnCxr03uew9O5xx3I9Oc1Bc0j4KMXJ2ReurmC0gaa6mjhiXq8jBQPxNcrq3xD0DS5/Lu5bkfJ5pcW7bVTJG8kj5UyCNxwvB54rMbxR4Ps9SzrfibSLnVEOHeS4TZbH+6BkrF+Jye5NV/FVrfXt9NqnhCPUvt1zaKkOoWN1bNZzFS2wTJIxyoLHLIpbaSAc4FcTxU29FZeZpywj5nXW/ijSpdZj0iWc2uqSx+bHa3ClHdM43LngjPHFWrLXdKvo7aSz1G1nS5ne2haOQEPKgZmQf7QCOSPRTXm2p+Dtc1LxO2v3kdq5Goxxi1VMTfZAhhLLL5mFAZ3uAu3dkAZz8tUPA/hjXrHWPDSPaqLex1OabUwZUzE4tJ44pcZ+YyLcRK2M48pePvY2o1+d8stxSimrxPaqKKK6TIKKKKACiiigAooooAKKKKACiiigAooooAK5P4n/8AIqyf9dU/nXWVyfxP/wCRVk/66p/Osq38OR3Zb/vdP1R4T4ouJbPwzq9zbOY54bOaSNwPusEJB/MVS8ZX11bWcFtp0kkV7dOQkkcLSlFVSxO0AkjIVTx/H+Nbs0Uc8MkM8aSRSKUdHGVYEYIIPUVnyQ6RoVvLfNBZWMUSnfMsaphTjIyB3IXjuQK8mLWh+g1oSd7Oya+7v+Hmjntc8SztaaXcad56ZgF/OkcDSEoMZibAO3OX5OMFOtdnG6yIrowZGAII6EVy/gjV4PEA1G+sbGK207zPIibywrzYLMzN7Zc4HqWPU108UaQxJFEixxoAqoowFA6ADsKc9PdsRhW5r2vNdP8ATt6nu/gr/kVdM/65D+ZrarF8Ff8AIq6Z/wBch/M1tV69P4F6H53i/wCPU9X+YUUUVZzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcZ8R/iJo3gK2tm1UXE1xc7vJt7dQWbbjJOSAByOfyzSlJRV2aUqU601CmrtnZ0V5p8Nvi9o/jjVpdMhtbixvQhkiSYhhKB97BHcdcen0r0ulGamrxKr4eph58lVWY2RFkjZJFDowKsrDIIPUGsPRQ9lPcaVKxdbYK8DE8mFshQfUqVK59APWt6sXVgLfWtMu+iy77Rz/vDcpP4pj/gVc2LheHN2Ck73j3/Q+OdZvb/wF8VdSuNNuP8ASbK+kIYcCRC2drD0IOCK+pdC8QJ4j8NaR4u06Ftyo3nwKcsY84kT3IKhh67fevmj4/6XJpnxS1UuD5d4Euoye4ZQD/48rD8K3/2cvHH9h+IG0LU7nZpmoHEW8/LHPwB9Aw4PvtrzU2ndH2GOw31rCQxEFeSS+atqj6viniljikjkVklAMZz94EZGPw5ptwIZ7WaOYo0LqY3yRjB4INee6rI+n6l4at2t7yaDSNaeRjbW0lwyW8ljdrGxVFLbQziPOOoFQzWd5e+MU061sb3/AIR7VLuDXJbiS3eNY2hXDQsGAKs0sVs+0jkNIe1e1Tn7SCkfGTjySsj4/wBStHsNRurOX/WW8rRNxjlSQf5V1/wSuHtvip4ceN9ha48sn1DKykfiDioPjDAlv8T/ABKka7VN67ke7fMf1JrE8JzSW3irRp4WKyx3sLqw7EOCK8he7P0Z+lSft8K/70fzR956zemwsWljQSTsyxxRk4DOxAA+nOT7A18+/tB6xqen3OieD7DUhYvrvmXGq6sxYExqCCMJyEA3HaOoUL0LZ921AG48RWML/wCqt4nucern5F/IF/zFeO/tA+HrqXxX4a8RRkJb20b2omEwhMEzMGRt7fKpPIBf5CwCNgPkddSpzVrPZfmfnD92CS6ngPhfU/D994jbw34fGs2kNzi10u6kvmHmzkbV86L7qrIxAymCmQcnFe+fDHVvsGl6frdk5S2kvotP1a3I2JKLjZ9nuwgAVJf3kayFQFYlz1UV55pfwysLfV/tYttStNUflrS10u5MsWVIYwg4iQnPDtK6KTwcgV6xpmntOU8MC2hh1C/vYtQ1O2hkV10uxgMYggZgSNzJFEgA67pGHAySrKL2M0ew1n3GjafcXMlxLbgzSY3sGYbsDA6H0AqXVYbm4sZIbG8FlcvgJP5Yk285Pyng5AIri9S8F+KL3UYbxfiDqdq0SgCK3s4VibBJyynIJ5x9AK4kk92aKTjrFnV/2Bpv/Psf+/jf40f2Bpv/AD7H/v43+NcvrWiePhCr6H4u09pR1ivNMVVb/gak7f8Avk1hNrPirSm2+L9WudHQf8vsenxXVn+Mq4KD3kRB71Sp32ZXtZ92ei/2Bpv/AD7H/v43+NH9gab/AM+x/wC/jf41iWena/e20VzZ+NIri3lXdHLFYQujj1BBwRU39ieJ/wDobf8Aymxf41PKu4e1n3Zq/wBgab/z7H/v43+NH9gab/z7H/v43+NfOenfCP4qL431zUbDxT/Ytlc6hcTrKLhj56tKzB/JTKc5ztJGM19AeHNI1mx0OSz13xFJq166FReLax2zJxjIVcjPfnNXOnGOzuL2s+7Ln9gab/z7H/v43+NH9gab/wA+x/7+N/jWMnhK/tkRrDxbrqXCgAtcNFcJJ/vIyf8AoJU+/aq99e+IvDEtpc6pf2WraNLcxW9w/wBmNvPb+YwRXyrFXUMy5G1SAScnFTyp7MftZ92dD/YGm/8APsf+/jf415T4nmmtPEF9b2080cMcmFQSNgD869V1z+2/3H9g/wBm/wAXm/bd/tt27fxzn2rwvxZ/wkn/AAkd/wCf/Y/mead2zzcZ9s0kuzPdyGo3WlzXenr1Rc+33n/P3cf9/D/jR9vvP+fu4/7+H/Gud/4qD/qFf+RKP+Kg/wCoV/5Ep69z6rmj/J+B0X2+8/5+7j/v4f8AGj7fef8AP3cf9/D/AI14tar8SP8AhIdQ+xFhafapdv2rHk7d5xs3fNt9Mdq7/wD4qoaT/wAwVtS/7aiL/GrlBx+0c1DFRrJ/umrd1v6HVfb7z/n7uP8Av4f8ajluriZNss8rr6M5Irxq6b4kf8JDp/20MLT7VFu+y48nbvGd+35tvrntXojXmuWvNxpdvdxjq1ncYfH+44A/8eolTa63+Y6GKhUb/duNu8f8jcrz34k6DJ4uu4NM0+4dLm1QzSlnPkpkfIGA/jJzg9gD6jPa2Go299YC8hciLndvG1kK8MrDsQQQfpVLwjGToyXki7Zr92vH9fnOVB+ibV/Cpg3B83VGuIhDFRVF6xlr8lYf4T0hdC8O2GnLjMEYDkdC55Y/mTWvRRUN3d2dEIKnFQjstD3TwV/yKumf9ch/M1tVi+Cv+RV0z/rkP5mtqvap/AvQ/M8X/Hqer/MKKKKs5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvnn9rPRJ5LfRNcjO63iLWkq4+6W+ZT9OGH5etfQ1c38RPDSeLvBupaMzKkk6AwyMOEkUhlP0yBn2JrKtDng4nbl2J+rYmFV7X19Hoz4i8K67d+GvEVhrGnkfabSTeobowxhlPsQSD9a+5ofEunt4NHieRymmCxOoOwBYpGE3twOSQAePavgq9tprK8ntLpDHcQSNFIh/hZTgj8xXtnwj8Yy694I1b4a3Jiiu77T7u10u5lYhN0kb/JIeSACxIIB44x0zxYSpyy5X1PqOIME69JV6au47+n/AAD6Eg8XaVIzJI1zbzJcQ20kVxbvG6PMcRZBH3WPAYcZ4znNSalPFrNpqtnpz77zT5UU5UhVnVUmVc9+GTOP71YE/gi4W38S2NtdB7XVI1ltrq6mkmuba5QDywWbJeNWVXXLZU7hyCMb3gvSbrSNCSPU3gk1S4lkur2SDJQzSMWYKTyVXIVc87VFehKKknF9T4yMnFqS6Hg/7UVtHfab4Y163UhZFkgckcjIDKD7jD18/AkEEHBHevq39oLQph4FvlizJYrcC9iGP9RLk7x/usruR6Nx3GPlKvFnBwfLLc++ySop4VJbJv8Az/U+t/hD48j8VWmm3NwcapbqNOvwT9/IzHL+JQj2LmvX6+A/CPiK88M6st7ZSFQcLKv95QwYfiGVSPcCvu/Rr+LVNJs7+3dJIrmFJVZDlTkZ4ruwUtHE+czzALDVFOHwv+v68j5F/aRtY7f4rag8YwZ4YZWH+1sC/wDsorgfDf8AyMWlf9fcX/oYr0b9pv8A5KlP/wBekP8AI1534WjebxPo8cSlpHvIVVR1JLjArlq/xX6n1WBf+xQb/lX5H3RqLC18Q2U8nENxE1tuPaTIZR+I3fiB61fuIIrmCSC4iSWGRSjxyKGVlPBBB4IqW9tIL22e3uoxJE+Mqcjocg5HQggHNZi6RdwZW01a5WHsk6LKV+jHk/iTXRXw03Pmj1Pz9SjKKTdmjCHw90aICKyn1mxs+hs7TVbiKEj0Cq/yD2TaKsRDTfC9jPp3hrTYzLGGnkii4CkjJeVzk5Pqcsfetf8AsaaY/wCnapeTJ/zziIgX80Ab/wAeqS7srex0G9htIlij8mRiB3JU5JPUn3NOlhZzkvaPQicoQi2tWeDeMfiVf31paX1vptvHf6VOL23dHOTtBDx/R0LofqD2FbsPxjvJokkj021ZHUMpEjcg9K8yPPWsvw5+709rUnJtJXtx/uqfl/8AHStfaPKMHzJOnp8/8z85WdY502/aap9l1+X9XPY/+Fv3/wD0C7X/AL+NR/wt+/8A+gXa/wDfxq8woqv7GwX/AD7X4/5mX9uY7/n4/uX+R0p8Z3+l6o2o+FrO105pXL3VhuY2l0T1Yp/yzc/30xn+INWhL+0H9ltpX1LTrayniGXglkO/P+z/AHh7j9K4qsHxZ4ag8RWyJLNLDLFkxspyoJ9V6H+dZV8nw/K5U6ab7Nv/ADOnC55iJTUK9RqPdJXX4f1+B7VB8ZLueGOaHTrR4pFDKwkbBB5Bp/8Awt+//wCgXa/9/GrwLwkt/wCH7K407V43eC3VpYJ4lLqydSvHOR1A9z6V1VvPFcwRzW8iyRONyupyCKKOV4KcU3Ts+2v+YsTmmOozajVvHo7Kz/A9m8M/E281fXrLT5NPt40uJNhdXJIrqvih/wAiLqf/AGy/9GpXivw8/wCR20f/AK7j+Rr2r4of8iLqf/bL/wBGpXzud4Wlhq8I0Y2TX6n0vD+LrYqhOVaV2n+iOprxLxl/yNGpf9dT/Kvba8S8Zf8AI0al/wBdT/KvCZ+gcOfx5+n6oxqKKKR9iFFbWi+HLvV7Rri2lt0RXMeJGYHIAPYH1q//AMIRqP8Az8Wf/fT/APxNaqjOSukcVTMcLSk4Tmk0ctRXU/8ACEaj/wA/Fn/30/8A8TXLupR2U9VJHFTKnKHxI0oYujiL+ylexxPjEnRhfz2p2x6nazxvH0H2hYmKOPQlVIPrgHtz2NvEsEEcSfdjUKPoBiub+INp9r0mxG4KV1C2wScfekCH9HNdRTk7xQqUeWtNdNLfO9/xPS7X4c2k1rDKb+cF0VsBBxkZqX/hWln/ANBC4/74Fdtpv/IOtf8Arkn8hVivTWHp22Ph55xjVJpVPy/yKekWK6bplvZo5dYV2hjwTVyiitkrKyPMlJzk5S3YUUUUyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4//aM8JSeH/HU2pQof7P1cm4RscLL/AMtF+ufm+je1eYWF5caffW95ZStDc28iyxSL1VlOQR+NfdfxB8J2njTwvdaRe4RnG+CbGTDKPusP5H1BIr4u8beD9X8GaudP1u3COwLRSod0cy5+8p/ocEdxXl4mk4S5lsfdZLmEMTRVGb95aeq/rc+nPhH8YbDxgYdK1ZVste24Az+6uSByUPZu+0/gT29Zr864ZZIZUlhdo5UYMrocFSOQQexr2Hwz+0B4m0uxS11K3tNVEYAWaXckpH+0w4P1xn1Jraji1a1Q8/MOH5OXPhdu3+R9XXdvDd20tvdRJLBKpV0cZDA9jXxP8YvBb+CfGNxaRKTptzmezc/3CeU+qnj6YPevoTwt8ePCWsCOPUXn0e6bgrcrujz7Ovb3YLVn45+Grbxr8O5L7THhubmwU3lrLEwYSIB86gjqCozx1KrV1oxrQvHdHJllSvluJUK8XGMtHfbyZ8c19kfs667FrPwzsrdQqz6azWkig+nzK34hh+INfG9a/hrxJrHhm+N3oOoT2U5GGMZ+Vx6Mp4YfUGuKhV9lK59PmmA+vUfZp2ad0egftN/8lSn/AOvSH+Rrm/gyA3xS8NhgCPtann6Gue8R67qPiTV59T1m5a5vJiNzkAAAcAADgAegrovgx/yVPw3/ANfQ/kaObmq8y7j9i6GBdKW6i1+B9xUUUV7B+cBVPWP+QPff9cH/APQTVyqesf8AIHvv+uD/APoJqofEiKnwP0Pk6svS/k1XWI+xmSUfjGo/9l/WtSsyw/5DWq/9sv8A0E19rP4o+v6M/LKXwz9P1RpkgAknAHU1yOo+KJTIyWKKiA43sMk++O1dhHK0E8Eq2X2/bKhNrkDzhuGV5yORnqD9D0qO7sjLf6dbak9yo1T7RYpBqllHb3EEjBPLfI6x+ZsAJ242uABzXk5pi6lJqnTdr6n0XD+XUcRGVasr2dkjibbxLfxsDKUmXuCoB/SuwsLpL20jni+646HqD3FMNr9mk1TTtFto5dc0u1gtUEcavIzbi10yDB3OrttBGSEBxgDito7an9pvE1mFobobGZXiEbcr1ZQBzgDOeT3rDLMZVlV9nN3TOvPssoQw/t6UVFq22l09NjUrGtAdL1Z7XygtneyGSBl4CSbcsmPfaWH/AAKtmsvxGNum+cOJIJY5UPuHHH4gkfjXuVVZc3Y+Tw7vL2b2lp/k/vO2+Hn/ACO2j/8AXcfyNdt+0p41m8HeDrZV0r7bb6jN5Dy/aPL8llKuvG07twVu4xjvXE/Dz/kdtH/67j+Rr0z9oPwtL4t+FuqWNnC819C0d1bogBJZGGcA99hcde9fJ8QW+tU+ba36s+y4W/3af+L9EdP8P/EE3ivwbpWu3Fh/Z738XnC283zdiknad21c5XB6d68y8Zf8jRqX/XU/yr1fwg1m/hPRW0wFbA2UBtw3UR+Wu3P4Yryjxl/yNGpf9dT/ACr5mW+h+k8Ofx5en6oxqKKKk+xOt8OaydJ0Wyijs5by4v8AUntYo42VfmFuZSSWIGNsTfjitK18d6dPpep3pt7qNbG1F08Tqu9wWkTauCQW3xOnBwTjBIINZOgeH7fxBo+nfbCrQWOqPdNCybhLm2eIL1GOZd2efu475GzrXg211DUtEntZVsbTTiFktIYQEniV0kSPjG0LJGjDA6bh/FXsUP4aPzjNf98qeprWOuWN7fyWUErNdRZDgRvsDLjcokxsLDIyASR3ryu5/wCPmX/fP869B0/wxLaeK5tYW9ijhk8wtbW0LxCUuRhpf3hRmGPvBFJzyeufPrn/AI+Zf98/zrnxv2T2uGN6vy/UwvFlra3OjSPf3Elvb2rrdu8eM/uzuxz9K0NOulvtPtbuNSqXESyqD1AYA/1rg/jZdX6+G4rLT7W4ljuZQJ5I0LBVBG1SR0LMVx9Md66fwI0jeDdGEyMkiWqRlXGCNo29Pwrkcf3al5nvwrp4yVJLaK1PqTTf+Qda/wDXJP5CrFV9N/5B1r/1yT+QqxXsLY/OanxMKKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYPjPwnpPjHR203W7cyw53I6HbJE395W7H9D3reopNJqzKhOVOSlB2aPlH4jfAjU/D9rJqHhyeTVrJMs8BTE8a+oA4f3wAfavGGBViGBBHBB7V+itcx4o8BeGPFDM+taPbTzkf69QY5f++1wT+NcdTBp6w0PpMFxHOC5cSubzW/3HwhU8N7dQQSQQXM8cMn340kIVu3IHWvpTxF+zjpk4d/D+sXNo/URXSCVPpuGCB+dcBdfs/wDjOKdkiGmzoOkiXGAfwIBrleHqR6Hu0s4wVZfGl66HkdFer/8ACg/G/wDzwsP/AAKH+FMm+A3jhI2ZbSykYDIRbpcn6ZwP1qfY1P5Tf+0sJ/z8X3nldekfs/aFe6v8StNuLSPNvpzfabiQ9EXBAH1JOAPqexqvpvwe8b3upR2j6JLahm2tPO6iJB3JIJyPpn2r6o+GPgey8CeHV0+1bz7mVvMurkrgyvj9FHQD+pNa0KEpSu1ZI8/Ns1o0qDhTkpSkraa79TrqKKK9Q+FCqesf8ge+/wCuD/8AoJq5VPWP+QPff9cH/wDQTVQ+JEVPgfofJ1cN4Y8Ty6h4tvbNtP8AKZ8+Y3nbvL8sEdNozk49K7muc0XRPsXivWtQ24S4CeWfqMv/AOPAV9hXjUc4cj0vr939fefmmEnRjSqqqru2nrdf8P8AI6CeJJ4XikGUdSpHsa4DUdIu7KRt8TPHniRRkEf0r0Kis8XgoYpK7s0a5bmtTAN8qunujzO2tZ7lwtvE8hJxwOK7zQ7D+z9PWJseax3OR61oUVng8vjhpc97s2zLOqmOiqfLyx+8Ky9dPmNp9oOTPdISP9lP3h/9AA/GrepXsOnWE93cttihQs3+A9z0rgPA9zrmq+IpNUuIGawk38ysQse7H+r9fugf4VvXrKMo0rXcvyObB4WU4TxDaSh36voke1fDz/kdtH/67j+Rr6J1TULXSrGW8v5fKto8b32lsZIA4AJ6kV87fDz/AJHbR/8AruP5Gvavih/yIup/9sv/AEalfK8SK+JgvL9WfU8Lf7tP/F+iGfC8+T4PttLfibSJJNMdfQQsUQ/QoEYezCvPvGX/ACNGpf8AXU/yruNQnXwn4z+3zuseia86RXEjYC296qhI3J/uyIqpk9GRB/Fxw/jL/kaNS/66n+VfOz3v3P0nhv8Ajz9P1RjUUUVB9ibmh+I7jSLNreGGKRWkMmXznJAH9K0f+E4vP+fW3/X/ABrkqK1VacVZM4amWYWrJznBNs63/hOLz/n1t/1/xrk5GLuzHqxzSUVM6kp/EzXD4Ojhr+xja5ieI/31xo1oP+W16sjD/ZjVpM/99Io/EVt1z+k/8TTXLvVW5trfdZ2nocH964+rALn0T3roKJaWRdH3m599vRf02fQ2m/8AIOtf+uSfyFWKr6b/AMg61/65J/IVYr2lsfmNT4mFFFFMgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKbJIkSF5XVEXksxwBQA6qesf8ge+/64P/AOgmj+09P/5/rX/v8v8AjVTV9SsW0q9C3tsSYHAAlX+6fetIxlzLQxqVIcj1Plms+ykdtX1JGdiieVtUngZXnFaFZemkNrOrFeQGjQn3CZI/Ij86+znvH1/Rn5dSXuz9P1RqUUUVZiFFFFAFPVLWzuYF/tFUa3jYSbZD8hI6ZHQ/Q1Cmtabu8tbmMY46ED88YrL8VaZqkkksrmF7WK3W7CRTq+IWcIHIB7sw+mazYvDV+YzNcG3tLcRxStNPKFUCRS0Y7ksygsAATjnpXg1s2caj9lFW7vqfY4XhxTop4ibv2Wyues/DshvGmjlSCDMCCO/Br2v4of8AIi6n/wBsv/RqV84fBm4mtfiJpul3EkUoSbKPHIJF6Z4YcEEc19H/ABQ/5EXU/wDtl/6NSvDzrERxFWnUXb9T1clwcsFGpSlrro+6sjoNSsLXVNPuLHUbeO5s7hDHLDKu5XU9QRXzp4gttR8Ma5eWafaNW0qGQpG5bddQr2DZ/wBaAOM/ewOjda+lK8S8Zf8AI0al/wBdT/KvDUraH3XD8eavKzs7fqjlNP1rTr+QxW10n2gDJgkBjlX6o2GH5VpVU1DT7PUYhHf2sNwg5AkQNg+o9D9KoL4fijG23v8AVIY+yLdMwH03ZOPbNHus+uvVjuk/w/D/AIJpWd5bXsQls7iG4jP8cThx+YqxXkfh74Rz2cyz3uuTQyDqLDKH8HP+FepabZ/YbRIBcXFxt/5aXEm9z9TV1Iwj8LuY4StXqq9any/O5NNLHBE8szrHEgLM7nAUDuSelc/Le3uvwmHSYpLXT5flfUJDsZk7+SnXkdGOAOozV+60KxvL03N4s1wdwZYpZnaJSMYxHnb2z061q1KaWxtKM6jtLReW7/y+X3kNpbQ2drFbWsaxwRKERF6KB0FTUUVJqkkrI+htN/5B1r/1yT+QqxWFY6/pcdnBGb2NnSNVbYCwBwOMgHmrMXiDR5W2pqdmH/uNKqt+R5r2Y1YbXR+X1KU+Zvlf3GpRSKwZQykFSMgg5zS1oYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXOfEb/kR9Z/64H+Yro65z4jf8iPrP/XA/zFbYf+LH1X5nNjP93qf4X+R8y0UVwPjfxZeWWt2un6IPMuIzulQJv3kjhMDnpzx6ivrq9eNCPPM/NcJhKmLqezp77+R12raj9j8uC3j8++myIYQcZ9WY9lHc/wBafpFmbGzEcjiSd2aWWQDG52OSfp2HsBUGg2XlW4u7lZTf3Cq07zY3g4+7xwAOwH861KqCcnzy/r/giqyjBeyh833f+Xbvv5IooqC+u4LG3ae6kEcS9WwT/KtG0ldmEYuTstyeiuH1H4kaVb5FlFPdt2ONin8Tz+ldL/bum/8APz/443+FYQxVGbajJaHVUy/E0knODV/Iguta0uy8Q6cji/lsIrD+zb5GhRHKFWUsnzkEjcGXOOVFVb/xFYayuqW+pC6tbaa8W6tXt41lMKqhjWIoWUEbNgB3cbehzwzWJNH1LDm68qcceYI2OR7jHNZI023kP+jTXtwB1aOybb+ZIB/CvnK2AnGbVOzXqj7jC5xSnSTrXjLro/zsdb8GreF/irpUlkZmtYZsq8qhWOVI5AJAzk8ZP1NfQHx0vbuHwfFZ6Wsst7d3SHyYkDPJDFmaXAP+xE31JUDkivCvhyl+niTSrPw/am0uWmGby+jyiHB+bYGBc+gyB719M+H/AApaaVevqV1cXGqa3KmyTUbwhpAvXYgACxpn+FAAe+TzXlZnRWHnBPe1/wATry/FfW+ea2vZeljY0vULTVdOt7/TbiO5s7hBJFNE2VdT0INOeztnYs9vCzHqSgJNYE/gLwxNcTTnR7eOSZzJJ5JaIMx6sQpAye570z/hX/hj/oGf+TEv/wAVXk+6empNbHQ/YbT/AJ9YP+/Yo+w2n/PrB/37Fc9/wr/wx/0DP/JiX/4qj/hX/hj/AKBn/kxL/wDFUe6V7SfcrWXjXwNe6vd6XDq+kLqNrO9tLbTFYnEiMVZQHA3YIPIyK6kWVmwBFtbkHkERivE4/wBmjwrP4h1HU9WvtQuo7m6lnS0iYRRxqzlghPLNgHGcjOK9Q0jwN4c0fw/Lomm6aIdMk2l4RNI2dpBHzFi3UetVNU18LF7Sfc3fsNp/z6wf9+xR9htP+fWD/v2K57/hX/hj/oGf+TEv/wAVR/wr/wAMf9Az/wAmJf8A4qp90ftJ9zofsNp/z6wf9+xR9htP+fWD/v2K57/hX/hj/oGf+TEv/wAVTW+H3hzrFa3Vs46SW1/cQuPoyOD+tHu9w9pPudTHGkSBI0VEHRVGAKSWKOVdsqK6+jDIrkbjw7rmkqtx4b1+9umjYE6fq0omhnXuvmlTKjejbmHqprT8MeJIdbe7tZrWfT9WsiourG4xvjz91gVJDo2DhgcHBHBBAHHS6JuSvpk+nbpdBkEQ+8bOTmF/p3Q/Tj1BrW0u9XULGO5RGj3ZDI2MowJVlOO4II/Cn1laLIYdd1exKsEzHdxnHGHBDD/vpGP4mujC1HGag3oy5fvItvdG7RWcNc0tjchdQtT9muEtJ8SD91M5ULG3oxLoAPVhSX+u6Vp8rR32o2tu6vEjCSQLhpCRGDnoWKnH0r0znNKioLe7t7iW5igmSSS2kEUyqcmNyiuFb0O11P0YVPQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc58Rv+RH1n/rgf5iujrnPiN/yI+s/9cD/MVth/4sfVfmc2M/3ep/hf5Hy9d3UFoitcSpEHOxSx6nBOPyBP4VmaXY6TpUX2yKSJpLlxuu5HDNKzH+97nsOKsazaT3cunfZ3eIxXBdpE2koPKkXOGyDywHTv+NZEmj3t5Z21jIsdvHAku+Vh5gkkbKh1AYEcM7c9Ca+sqOXNdRvbb8D86oxhyWc7J7/j/wAD79jpZLiGKaKKSVFllJEak4LYGTj14qSuYurHVbx0vXSKO5toovLiIDF3BDuFYNhQxAXkdu1dPWkJuTd1YwrUowStK76/1/Wtz0nwJ8O7TxLoCahPfTwO0jJsRARx9a6L/hTlh/0Fbr/v2ta/wW/5EeL/AK7yfzru6+dxWOrwrSjGWifkfbYDKcHVw1Oc4XbS7/5njOo/s++GtRybyV5GPV/JVW/76GDWp/wpyw/6Ct1/37WvUqK5ljq8W2pb+S/yO6WU4SSUZQultq/8zy3/AIU5Yf8AQVuv+/a0f8KcsP8AoK3X/fta9Soqv7RxP8/5Ef2Lgf8An2vx/wAzzfSfhZbaXqNve2uq3Angbem6JSM12H9nal/0Fz/4DLWxRXHiW8VJSratHfhKFPBxcKEUk9e/5mP/AGdqX/QXP/gMtH9nal/0Fz/4DLWxRXN9VpdvzOr20vL7l/kY/wDZ2pf9Bc/+Ay0f2dqX/QXP/gMtbFFH1Wl2/MPbS8vuX+Rj/wBnal/0Fz/4DLR/Z2pf9Bc/+Ay1sUUfVaXb8w9tLy+5f5GP/Z2pf9Bc/wDgMtH9nal/0F//ACWWtiij6rS7fmHtpeX3L/IwdP1KSOdbDWAsN/nCOBiO4A/iQ+vqvUfTmtalvbO3vrZ7e7hSaFuqsM/j7H3rLbSb22Qf2dqk52kYiuwsqEem7Afp3ya5amElH4NUVeE9dn+Bp1zvizw/Jqn2fUNJnSy1+yybS6IJUgkFopAPvRvjBHbhhyBV573ULM/6fp5li/57WRMuPqhAYfhuqxYalaX5dbWYNIn342BV1+qnBH4iuZqUHqrA6btfoc1pnxB0d7i003WpRpHiGaYWx0u4OZfNPTZgfPGccSD5T7HIG1dyNZ+IIZo42lae0ljWNSAZHQh1UEkDJBfrXgH7QHwo1O28Rp8QvBguLq+t547u6s9zO6shBEkfcgbRlR06jjge9tMviDw5YanpRRmlSG/tCxwDkBgM9gykrn0Y1r7sHGpEKb1s+pxGi+Atdgtb211Ge0f+29MkF3NbxeWbW+ErTJIcu28755fmUD/VpxjGLS+FtW1vQIZfEemRrqOp6vHd6laCZXWGBU8oIGBwRsVTgd2b3NeiaVfJqNklxGjRkkq8b/ejcHDKfcEGrleqmpK6MWnF2Zw/gKz1TQLTxXdeJ8Atf+elzvVjcQRWlvEJjg/KW8liQcYOe2DXyqnxK8SL40HiP+0bh5xP5nkNIfKKf889vTbt4/XrzX158TYJ7n4eeJIrRiszafPjHUjYcj8RkfjXwfXDjJtNJH1XDmHp1IVJTV+ny/4P6H374Q8R2Hivw/aavpb7oJ1yVP3o2H3kb3B/x6Gtmvlr9lrxUmneI7zw/dPth1JRJBk8CZAcj/gS5/75A719S11UantIcx4eZYP6niHTW269P60CiiitTgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKy/E+mvrGgX2nxSLG9xGUDsMgVqUVUZOLUluiZwVSLhLZ6Hiv8Awpy//wCgra/9+2o/4U5f/wDQVtf+/bV7VRXf/amJ/m/BHj/6v4H+V/ezxX/hTl//ANBW1/79tR/wpy//AOgra/8Aftq9qoo/tTE/zfgg/wBX8D/K/vZz3gTQJfDegJp886TusjPvQEDn610NFFcM5upJzluz1qVKNGCpw2WgUUUVBoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWbrWlR6jDvQ+TfRg+Rcrw0bdue6+q9DWlRUyipKzKjJxd0ZWkXxvrTdInlXMbGKeLP8Aq5B1H07g9wQa8Vh+I9z4M+Leq+H9fbZ4fknH2ckYFqHUMpH+xzyO34V7Fqaiw1u1vkG2K7ItbjHTd/yzY++cr/wIelfN37U+nR23jawvUdi93aAOp6AoxGR+BH5V49SDpycWe3lVKlXrOlNaTT+TPouGeOx1WK6t5Uk03VGUFkYFVmx8rgjjDgAfUL6mujr5t/Z68ZW+o6XJ4J1uUqSC1hJuweu4oD2YH5l/+sK9jPiC9iuPDVm/lGe51SXTr0leoS0uJQy+m4xRt9GIrrwdX/l2zjzDCSw1Rxl0/FdH+jOtkRZI2SRQyMCGBGQQe1fBnxB0IeGfGusaQmTFbXBEWevln5kz77SK+vr3xRfwavdaKog/tRtUt4LTKHDWsiea0hGeqpFcge8Y9a+c/wBpaFIvireOgAaW3hdz6nZt/kBV4yPuJnpcN1XHESp9Gvyf/BOF8F3ctj4v0S6tziWK9hdfwcV9+1+dSO0bq6MVdSCCOoNfoVo9w93pNlcy48yaBJGx0yVBNTgnujfieGtOfqvyLdFFFdx8qFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnXxw8cT+CPCQm04H+07yTybaQqGWI9WYg9cDoPUivAvA/xo8S6V4jt59e1KfUtLdtlxDIASqk8smAMMOuOh6e4+g/jh4VbxZ4Avbe1g87UbXF1agD5iy/eUfVSwx64r4oPHWvPxU5wmmnofX5HhsNiMLKMopyvr38rdv8z9EraeK5t4p7dxJDKgdHXoykZBH4VJXlX7OniyHX/AdvpskudR0lRbyIepj58th7bfl+q/SrPhvxfrGreJZNMSeBme51OJo2sZIxbxW9w8MUqyE7ZeRGGC55b+HBB7oSU4qSPl8TQlh6sqUujO+1uzN/pN3bKcSSRkIf7rjlT+BAP4V85/tPW731j4X19OIZYmhdf7jEBwP/AEIfhXs/hLxVd+IL/TYVjij8vTTcaogBJiuTJ5QiBz0DxXIP+4vrXH/GTQ21X4feINNhw1zpVz/aUMfcxHLEj2AeUf8AAcVxY2O0vkd+T1vZYiLfR/g9H+h8raVfz6Xqdpf2bbLi1lWaNvRlOR/Kvr7Tb3QvHFro/iGD7QbOS4VZViuZLeW1u9jRq26NlOdsrRnnBDqe1fG9d98IvF0vh/WH025uDHpGp4hlyeIZP+Wcw9NrYz7fQVxRk4NSXQ+rzbArE0+Zbr8V1/zXmfX8PhnSYdYtNWFs0mp2ls1pFczTSSyCInJBLMdxznk5IyQDgnPzl+1hZRQ+MtKu0GJLiy2v77HOD9cNj8BX01pF39v0y1uiuxpYwzL/AHWxyPwORXzf+1t/yMWgf9er/wDodeniWpUro+YyK8cco+v5HgtfeXw31JtX8BaDfPGI2ls49yg5AIGDj8q+Da+7vhdYSaZ8O/DtrP8A61LKNmHoWG7H4ZxXPgviZ7HE1vZQ73/T/hjqKKKK9E+NCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr4u+PXhZ/DPxCvmRMWWosby3YDj5j86/g2ePQj1r7Rrzz43+CD418HvHZoDq1iTPaernHzR5/2gB+IWsMRT9pDTdHrZNjVhMQnL4ZaP/M+T/h/4svPBfie11ex+cJ8k0OcCaI/eU/zHoQDX2T4Yt/DWv6LpmqaKgktVuZdQt5ElYPFPK7vLkg5GWkfchO3nGMYFfCjqyOyOpVlOCCMEH0ruPhV8RNQ8Bax5ke640qdh9qtM8MP76+jj9eh9uLD1/Zvlex9LnGVfXI+0p/Gvx8v8j7K0fQdM0a51K40y0S3m1G4N1dMpJ8yQjBbk8euBgZJPUkluvaQupRLJEwhvYgRFNjIweqMP4kPcf1qr4T8X6F4ss/tGhajDc4GXiztkj/3kPI+vT0rfr0Wo1I2eqZ8Q1OjOzVmj8/fFOlyaL4i1DTpY2ie3mZNjZyo7D8sc96y6+nP2mPAD6jZr4q0mHdc2qbL5EHLxDpJjuV6H/Z9lr5jryatN05crP0bLsZHGUFUW/X1PsP9nPxHJr/w/WK7mMt3YTtA+VwdpwynPfqfyrzb9rb/AJGLQP8Ar1f/ANDrH/Z9+I+l+DJdR0/XzLFZ3ro6XCJvETAEHcBzggjoD096n/ad1vS9b1zQptH1C1vo1tGLNbyhwuWyAcdD7HmulzUsPa+p4dHCToZs5cvuu7T6bf5ni1foL4b/AORd0v8A69Yv/QBX59V+gvhv/kXdL/69Yv8A0AUYLdj4n+Gn8/0NGiiivQPkAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPBPjX8GG1e5uvEHhRAL+TMlzY9BM3d09GPcd/r1+Z54ZbeZ4biN4pY2KujqVZSOoIPQ1+idcn44+H3h7xnbsusWSi6xhLyHCTJ6fNjkexyPauOthVL3o7n0eW59KhFUq6vHv1X+Z8MQTS28qywSPFKvKujFSPoRXe+C/i54s8K4ihvft9nn/j3vsyKP8AdbO5fwOPatzxj8B/FGiySS6OI9ZsgSVMJ2zAe6Hr/wABJryu/sbvTrlrfULWe1uF+9FPGUcfUHmuJqdJ9j6eM8Lj4WVpL+vmj6c8P/tDaBfWrx+ItNurGXbgiICeOT1HYj6EfjXzDfPDJe3D2qGO3aRjGh6queB+VQ0UVK0qiXN0DCZfRwcpOjpzdLhRRRWR3BX6C+HAR4e0sEYItYgQf9wV8bfBfwhN4u8cWUZh36bZutzeMw+XYpyEPuxGMemT2NfbVehgotJyPj+Ja8ZThSW6u38woooruPlwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqhq+j6brNv5GrWFpew/3LiJZAPpkcVfooauNScXdHmOofA7wNeXBlXTp7bPVILhwv5EnH4VW/wCFCeCP+eF//wCBR/wr1eis/Y0+x2LMcWlZVH97PKP+FCeCP+eF/wD+BR/wrHb9nLw6dQEqarqYtNwJgOwnHpux/Svb6KToU30LjmuMjtUZm+H9D03w9pken6LZxWdpH0SMdT6k9Sfc81pUUVolbRHBKTk+aTuwooopiP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sinoatrial node (SAN) generates an action potential that is conducted through the right and left atria, resulting in atrial contraction. The impulse is then conducted through the atrioventricular node (AVN), activating the ventricular myocardium, resulting in contraction of the right and left ventricle.",
"    <div class=\"footnotes\">",
"     SVC: superior vena cava; IVC: inferior vena cava; PV: pulmonary veins; LAA: left atrial appendage; RAA: right atrial appendage.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrical activity in atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During atrial fibrillation there are multiple reentrant circuits within the right and left atrium, resulting in nonuniform activitation of the atrial myocardium. These circuits, which produce multiple wavelets, often occur around the normal structures of the atrial including the orifices of the superior (SVC) and inferior (IVC) vena cavae, the orifice of the pulmonary veins (PVs), and the right (RAA) and left (LAA) atrial appendages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29669=[""].join("\n");
var outline_f28_62_29669=null;
var title_f28_62_29670="Treatment of postpartum psychosis";
var content_f28_62_29670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of postpartum psychosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/62/29670/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29670/contributors\">",
"     Shari I Lusskin, MD, FAPA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29670/contributors\">",
"     Shaila Misri, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/62/29670/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29670/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/62/29670/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29670/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/62/29670/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are more likely to experience psychosis during the period following childbirth than at any other time in their lives. Postpartum psychosis appears to be a heterogeneous group of mood and psychotic disorders. These disorders have in common the emergence of psychotic symptoms such as delusions and hallucinations in the first weeks postpartum.",
"   </p>",
"   <p>",
"    The onset of psychosis during the postpartum period constitutes a medical emergency. Women with postpartum psychosis appear more likely to commit suicide or homicide than the general population. Acute management emphasizes hospitalization to ensure safety, antipsychotic medication, and treatment of the underlying disorder.",
"   </p>",
"   <p>",
"    The treatment of postpartum psychosis is reviewed here. The diagnosis and treatment of individual mood and psychotic disorders are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link\">",
"       \"Postpartum psychosis: Epidemiology, clinical manifestations, and assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"       \"Overview of psychosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"       \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"       \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;General principles of treatment include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early identification of psychotic symptoms",
"     </li>",
"     <li>",
"      Emergent evaluation",
"     </li>",
"     <li>",
"      Hospitalization for safety and acute management",
"     </li>",
"     <li>",
"      Pharmacotherapy",
"     </li>",
"     <li>",
"      Coordination of care among clinicians",
"     </li>",
"     <li>",
"      Involvement of family and other support systems for the patient and the newborn",
"     </li>",
"     <li>",
"      Psychoeducation for the patient and family members",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ensuring safety and initiating treatment with appropriate psychotropic medications are the initial priorities of clinical management. Important next steps include evaluation and testing to exclude other medical causes of psychosis, and diagnosing and starting treatment for an underlying psychiatric disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link\">",
"     \"Postpartum psychosis: Epidemiology, clinical manifestations, and assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman experiencing psychosis will not be able to care for herself or her baby; she should be hospitalized until stable. The mother should not be left alone with the infant. Inpatient mother-baby units are not available in many countries. Though uncommon, hospitals may make provisions for supervised day-time visits with the infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After ensuring safety, the next priority is to treat symptoms of psychosis, agitation, and insomnia with medication. &nbsp;Symptomatic treatment of psychosis and agitated behavior is necessary while the diagnostic evaluation is underway.",
"   </p>",
"   <p>",
"    Pharmacotherapy in this population needs to be considered in the context of the mother's status regarding breastfeeding. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Breastfeeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Antipsychotic medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medications are typically the first-line treatment for psychosis and agitation in postpartum psychosis. There are no controlled trials comparing antipsychotics to placebo or to other interventions for postpartum psychosis. However, randomized trials demonstrate their effectiveness in reducing psychosis in bipolar disorder, psychotic depression, and schizoaffective disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Our experience suggests the rate of adverse effects from antipsychotics is comparable to that in non-puerperal psychotic disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Breastfeeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We prefer prescribing atypical antipsychotics over the typical antipsychotics because of their mood stabilizing properties and lower risk of extrapyramidal symptoms and tardive dyskinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/5\">",
"     5",
"    </a>",
"    ]. Given that women with postpartum psychosis may continue to provide breastmilk for their infants and may get pregnant again, the choice of agents should be restricted to those with better safety data in pregnancy and lactation. &nbsp;We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"     Iloperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    because of longer clinical experience and the safety data in pregnancy and lactation. Careful monitoring is advised because the atypical antipsychotics can cause hyperglycemia, hyperlipidemia, and weight gain, as well as extrapyramidal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be treated to remission. Treatment should be continued for at least one year to reduce the risk of relapse; some patients will merit life-time prophylaxis due to potential for relapse without medication and risk factors such as suicidality.",
"   </p>",
"   <p>",
"    For mild agitation, we recommend starting oral doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/d),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    (2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/d),",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    <span class=\"nowrap\">",
"     (50/d",
"    </span>",
"    to 50 mg po bid initially). The medication may then be titrated up to a therapeutic dose over the next three to four days (risperidone 2 to 4",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    olanzapine 10 to 15",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    quetiapine 300 to 800",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    The dose should be titrated upward with the goals of achieving remission while minimizing side effects. More severe cases with agitation and sleeplessness nonresponsive to individual agents may need low doses (0.5 to 1 mg) of risperidone in addition to quetiapine.",
"   </p>",
"   <p>",
"    If parenteral medications are required, eg, for involuntary administration, then intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    may be used in conjunction with oral medications. For mild agitation, 0.5 to 2 mg of haloperidol may be sufficient; higher doses can be used for moderate (2 to 5 mg) or severe (5 to 10 mg) symptoms. An intramuscular injectable form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    is an alternative, with a recommended dose of 10 mg, repeated at intervals of two to four hours, up to a total of 30",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    We recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    be reserved for patients who fail to respond to the preferred treatments. Side effects should be monitored and treated accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of psychosis\", section on 'Voluntary versus involuntary treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When conventional antipsychotic medications are used, the high-potency agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"     trifluoperazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"     thiothixene",
"    </a>",
"    are usually recommended. Limited data had suggested that low potency antipsychotics were less teratogenic (for subsequent pregnancies). However, the decision as to which drug to use should be made on a case by case basis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"     Benztropine",
"    </a>",
"    (0.5 mg orally twice daily) is often administered in conjunction with typical neuroleptics to reduce extrapyramidal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link&amp;anchor=H28219024#H28219024\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\", section on 'Extrapyramidal symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other psychotropic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not evaluated in controlled trials in postpartum psychosis, benzodiazepines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    have been found to be effective adjuncts to antipsychotics in inducing sleep or controlling agitation in other psychotic disorders. Early intervention to promote sleep in postpartum psychosis may avert or attenuate the psychotic episode. Lorazepam 0.5 to 2 mg can be administered orally or intramuscularly in conjunction with antipsychotic agents to reduce agitation. It can be repeated as needed up to a maximum 8",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link&amp;anchor=H18522653#H18522653\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\", section on 'Management of agitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other psychotropic medications, such as mood stabilizers and antidepressants, are used based on the patient's primary diagnosis (eg, bipolar mania and bipolar depression, unipolar depression, or schizoaffective disorder). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electroconvulsive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient does not respond to or tolerate antipsychotic medication, we suggest electroconvulsive therapy (ECT).",
"   </p>",
"   <p>",
"    There are no randomized trials of ECT for postpartum psychosis. A retrospective study comparing ECT use in 58 women with postpartum psychosis to 56 matched, non-puerperal women with psychosis treated with other interventions found that the women with postpartum psychosis had a greater rate of improvement on a four-point rating scale [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/6\">",
"     6",
"    </a>",
"    ]. Randomized trials in non-puerperal patients have found ECT to be effective for psychotic depression but inadequate to treat mania [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ECT may be useful if a rapid response is needed to prevent harm, eg, the woman is acutely agitated or at high risk for suicide or infanticide. The number of treatments will depend on the severity of the symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of resistant depression in adults\", section on 'Electroconvulsive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ECT has a relatively low rate of adverse effects in the general population, including time-limited neurocognitive effects, rare cardiovascular or pulmonary compromise, and risks associated with general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial psychotic symptoms are under control, psychotherapy can provide useful adjunctive care. Modalities shown to be effective are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of breastfeeding need to be weighed against risks to the infant for each psychotropic medication. All psychotropic medications are transferred into breast milk, and thus are passed on to the nursing infant. &nbsp;However, the effects of some of these medications are believed to be clinically insignificant. Guidance regarding specific medications is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=see_link\">",
"     \"Use of psychotropic medications in breastfeeding women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some women will only take their medications if they are allowed to breastfeed. In these cases, the benefits of medication may supersede concerns about use of the drug in lactation, particularly concerns founded on limited data. Women with mild to moderate illness may be able to breastfeed. They should be monitored to ensure adequate rest and sleep. Patients who are more severely ill may be too disorganized or present too much of a risk to the baby. Women with psychosis should not be left alone with the baby at any time.",
"   </p>",
"   <p>",
"    There are no known effects of ECT on breast milk. The American Psychiatric Association Task Force on ECT recommends that the informed consent process include a discussion with the mother of potential risks to the infant of breastfeeding during a course of ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/8\">",
"     8",
"    </a>",
"    ]. Anesthetic medications administered during ECT treatment generally pose little risk to breastfeeding infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/9\">",
"     9",
"    </a>",
"    ]. Exposure can be minimized by delaying breastfeeding for a few hours after ECT therapy or by collecting and storing breast milk the day prior to ECT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Coordination of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have experienced postpartum psychosis, but choose to discontinue their mood-stabilizing medication after hospital discharge are at increased risk for recurrence. During the inpatient stay, clinicians should coordinate aftercare with the patient's outpatient psychiatrist, obstetrician, primary care physician, and pediatrician. Each clinician can play a role in monitoring the patient for recurrence and encouraging continued medication adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with bipolar disorder or a history of postpartum psychosis can be identified though screening during prenatal care. They should be educated about their increased risk of developing psychosis following childbirth. They should be monitored for the first few weeks postpartum for early indications of psychosis or mood instability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link&amp;anchor=H14#H14\">",
"     \"Postpartum psychosis: Epidemiology, clinical manifestations, and assessment\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insomnia, which can be an early symptom of a mood disorder and a trigger for an episode of postpartum psychosis, can be treated postpartum with a benzodiazepine, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 to 2 mg orally at bedtime. Irritability, a potential symptom of mood instability, can be treated with one of the antipsychotics discussed above.",
"   </p>",
"   <p>",
"    Mood stabilizers should be used prophylactically postpartum in women previously diagnosed with bipolar disorder or postpartum psychosis. They can be started immediately following childbirth, though issues regarding breastfeeding should be considered. The choice of mood stabilizers should be based on the patient's history of response and the safety data of the medication during lactation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Breastfeeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two small retrospective studies have found relatively low rates of relapse for women with bipolar disorder who are treated with mood stabilizers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A small observational study suggested",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    5-10 mg at bedtime may prevent relapse, but larger and better controlled studies are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A sample of 29 women with a history of postpartum psychosis was followed over the course of a subsequent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/13\">",
"     13",
"    </a>",
"    ]. All 29 women remained stable during the pregnancy without treatment with a mood stabilizing medication. Advised to start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    prophylaxis immediately postpartum, none of the 20 women who took lithium after delivery experienced symptoms of relapse (ie, any manic, psychotic, or depressive episodes), while four of the nine patients who declined prophylactic lithium experienced subsequent relapse.",
"   </p>",
"   <p>",
"    In our clinical experience many women who have been maintained on therapeutic doses of mood stabilizers in pregnancy develop mood instability postpartum. They require close observation and may require adjunctive treatment with an antipsychotic.",
"   </p>",
"   <p>",
"    Three reports have described a total of 14 women with postpartum psychosis who experienced a reduction in psychotic symptoms associated with the administration of estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29670/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, numerous methodologic flaws in these reports limit the conclusions that can be drawn. We do not support use of estradiol for this population.",
"   </p>",
"   <p>",
"    Education is an important component of prevention. Patients at risk for postpartum psychosis and their partners or other family members should receive education about risks and early signs of a mood or psychotic disorder (eg, insomnia or irritability), and plan for accessing treatment quickly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ensuring safety and initiating treatment with antipsychotic medication are initial priorities of clinical management. Important next steps include examination and testing to exclude medical causes of psychosis, and diagnosing and starting treatment for the underlying psychiatric disorder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend atypical antipsychotic medication first-line for postpartum psychosis over other treatments (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). For initial management,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      can be started at 0.5 mg daily and titrated rapidly to a therapeutic dose of 2 to 4 mg per day.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      is an option for patients with more severe agitation and sleep deprivation (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Antipsychotic medication'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest benzodiazepines as treatment adjunctive to antipsychotic medication over other treatments for agitation and insomnia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other psychotropic medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest electroconvulsive therapy for postpartum psychosis that does not respond to antipsychotic medications, if antipsychotics are not tolerated, or when rapid response is needed to reduce risk of harm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Antidepressants or mood stabilizers may be indicated based on the diagnosis of the underlying mood or psychotic disorder. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other psychotropic medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient has a history of responding well to a particular mood stabilizer, the medication should be restarted as soon as possible after child birth (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Other psychotropic medications'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The benefits of breastfeeding need to be weighed against risks to the infant for each psychotropic medication based on limited information. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Breastfeeding'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=see_link\">",
"       \"Use of psychotropic medications in breastfeeding women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/1\">",
"      Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/2\">",
"      Ghaemi SN, Goodwin FK. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol 1999; 19:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/3\">",
"      Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. Br J Psychiatry 2006; 188:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/4\">",
"      Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/5\">",
"      Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/6\">",
"      Reed P, Sermin N, Appleby L, Faragher B. A comparison of clinical response to electroconvulsive therapy in puerperal and non-puerperal psychoses. J Affect Disord 1999; 54:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/7\">",
"      UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799.",
"     </a>",
"    </li>",
"    <li>",
"     Association, AP. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging: A Task Force Report of the American Psychiatric Association. 2nd ed. Washington, DC: American Psychiatric Association; 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/9\">",
"      Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/10\">",
"      Cohen LS, Sichel DA, Robertson LM, et al. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995; 152:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/11\">",
"      Austin MP. Puerperal affective psychosis: is there a case for lithium prophylaxis? Br J Psychiatry 1992; 161:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/12\">",
"      Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disord. 2006;8(4):400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/13\">",
"      Bergink V, Bouvy PF, Vervoort JS, et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 2012; 169:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/14\">",
"      Ahokas A, Aito M, Rim&oacute;n R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry 2000; 61:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/15\">",
"      Ahokas A, Aito M, Turiainen S. Association between oestradiol and puerperal psychosis. Acta Psychiatr Scand 2000; 101:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29670/abstract/16\">",
"      Ahokas A, Aito M. Role of estradiol in puerperal psychosis. Psychopharmacology (Berl) 1999; 147:108.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6964 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-AFC96612BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29670=[""].join("\n");
var outline_f28_62_29670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Antipsychotic medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other psychotropic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Coordination of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=related_link\">",
"      Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=related_link\">",
"      Use of psychotropic medications in breastfeeding women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_62_29671="Trigeminal nerve danger zones";
var content_f28_62_29671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60544%7EDERM%2F59570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60544%7EDERM%2F59570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Danger zones for supraorbital, supratrochlear, infraorbital, and mental branches of the trigeminal nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trigeminal nerve danger zones. The supraorbital and supratrochlear nerves (area 1). The infrarobital nerve (area 2). The mental nerve (area 3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Danger zones for temporal, marginal mandibular, buccal, and zygomatic branches of the facial nerve. Danger zones for the great auricular and the spinal accessory nerves, and the parotid gland.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Facial nerve danger zones. The frontal branch (F) of the facial nerve where it crosses the zygoma (area 4). The marginal mandibular (M) nerve where the superficial musculoaponeurotic system is thinned in the lower face (area 5). The parotid duct (PD) and the buccal (B) and zygomatic (Z) branches at the anterior border of the masseter muscle (area 6). The great auricular nerve (GAN) and the spinal accessory nerve (SAN) at Erb's point on the posterior margin of the sternocleidomastoid muscle (area 7). The parenchyma of the parotid gland (P) (area 8).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29671=[""].join("\n");
var outline_f28_62_29671=null;
var title_f28_62_29672="Rapid drug desensitization for immediate hypersensitivity reactions";
var content_f28_62_29672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid drug desensitization for immediate hypersensitivity reactions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/62/29672/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29672/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29672/contributors\">",
"     Roland Solensky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/62/29672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29672/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/62/29672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/62/29672/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/62/29672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization is a procedure that alters the immune response to the drug and results in TEMPORARY tolerance, allowing the patient with a drug hypersensitivity reaction (ie, a drug allergy) to receive an uninterrupted course of the medication safely. Once the medication is discontinued, or if treatment is interrupted for a sufficient period of time, the patient's hypersensitivity to the medication returns.",
"   </p>",
"   <p>",
"    The terms drug hypersensitivity and drug allergy are used synonymously in this topic review.",
"   </p>",
"   <p>",
"    The World Allergy Organization (WAO) has recommended dividing drug hypersensitivity reactions into two general types [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reactions are reactions that begin within one hour of exposure to the culprit drug",
"     </li>",
"     <li>",
"      Delayed reactions are reactions that begin later than one hour after exposure to the culprit drug",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Techniques for drug desensitization in patients with immediate hypersensitivity reactions, as well as the proposed mechanisms underlying these techniques will be reviewed here. Desensitization for immediate reactions to nonsteroidal antiinflammatory drugs (NSAIDs) is NOT included in this discussion, but is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=see_link\">",
"     \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMEDIATE DRUG REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The desensitization techniques described here are appropriate for IgE-mediated reactions, and they have been employed with success to some non IgE-mediated immediate hypersensitivity reactions as well. Different techniques are used for desensitization in patients with delayed reactions. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Application to other types of drug allergy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     IgE-mediated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many, but not all immediate reactions are IgE-mediated, Gell and Coombs type I hypersensitivity reactions. These reactions are the result of degranulation of mast cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophils, and are characterized by flushing, pruritus, urticaria, and angioedema. Anaphylaxis, the most severe form of type I reaction, presents with laryngeal edema, cough, wheezing, shortness of breath, nausea, vomiting, hypotension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiovascular collapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs that are well-known to cause IgE-mediated allergic reactions include penicillins, cephalosporins, and platinum-based chemotherapy agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/2\">",
"     2",
"    </a>",
"    ]. A number of other drugs have been implicated in causing IgE-mediated reactions, albeit less commonly than the three groups mentioned previously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H21#H21\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Platinum drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Non IgE-mediated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate reactions that are clinically similar and equally severe can also arise from non IgE-mediated activation of mast cells and basophils. These reactions are well described with taxane chemotherapy agents and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/3\">",
"     3",
"    </a>",
"    ]. These reactions can be clinically identical to IgE-mediated reactions, although some reactions include other features, such as sudden chest tightness or back pain (seen with the taxanes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H32#H32\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Taxanes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"     \"Vancomycin hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROPOSED MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization results in temporary tolerance of mast cells and basophils to the specific drug in question. Reduced skin sensitivity is observed following desensitization in most patients with IgE-mediated reactions, and some become skin test negative at the end of the protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which temporary tolerance is induced during drug desensitization is not fully defined [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ]. In vitro studies have demonstrated that subthreshold doses of antigen (in this case, the allergenic drug or some form of it), given prior to activating doses, can render mast cells and basophils unresponsive to activation by that specific antigen, but still responsive to other activating stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Subthreshold doses of antigen might result in monomeric binding to the IgE receptor (Fc epsilon R1) leading to internalization of the antigen-receptor complex, but without cross-linking, such that the cell does not become activated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both IgG and IgE antibodies specific to the antigen increase after desensitization therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/7\">",
"     7",
"    </a>",
"    ]. The rising IgG titer may neutralize drug epitopes and serve a \"blocking\" function for IgE-dependent reactions, although this has not been conclusively demonstrated in maintaining drug desensitization.",
"   </p>",
"   <p>",
"    At a molecular level, the transcription factor STAT 6 was shown to be necessary for desensitization in a mouse model of rapid antigen desensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, rapid in vitro desensitization of human mast cells and basophils results in a reduction in levels of certain signaling molecules, such as syk kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In keeping with the concept that changes in syk are important in both normal activation and in desensitization, naturally-occurring syk-deficient basophils are unresponsive to drug antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/15\">",
"     15",
"    </a>",
"    ]. The functions of syk in mast cell signaling are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link&amp;anchor=H16#H16\">",
"     \"Mast cells: Surface receptors and signal transduction\", section on 'Signal transduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintaining the desensitized state is dependent upon continuous exposure to the drug. Basophils can be desensitized in vitro to penicillin, but if basophils are isolated from a patient who was just desensitized and challenged in vitro with penicillin, the cells will activate, demonstrating that the drug must be physically present to maintain the desensitized state [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS AND PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization should be considered in patients who are either proven (by positive skin testing or in vitro tests for drug-specific IgE) or are strongly suspected to have an immediate type allergy AND for whom there are no acceptable alternate drugs. A standardized protocol, used at one of the author's institutions, has been successful in patients with immediate hypersensitivity reactions to a variety of drugs. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Standardized protocol'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Drug desensitizations can be performed in patients of any age. Desensitizations have also been safely performed in pregnant women (usually in order to administer penicillin to a penicillin-allergic woman with syphilis) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Preparing the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to desensitization, the patient's underlying medical problems and medications should be reviewed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When possible, beta-adrenergic-blocking medications taken for hypertension should be withheld for 24 hours prior to desensitization. This is usually straightforward if the patient is taking low to medium doses of these agents for hypertension. However, patients taking high-dose beta blockers and individuals taking these medications to control arrhythmias should NOT stop these medications unless under the guidance of a cardiology specialist. Beta-blockers are continued through the procedure in some cases, if stopping them is considered too risky.",
"     </li>",
"     <li>",
"      Patients with asthma, chronic obstructive lung disease, or other lung diseases should be optimally controlled prior to undergoing desensitization, in order to minimize the chances of respiratory symptoms during a potential allergic reaction. Asthmatic patients with active symptoms are sometimes treated with a brief course of oral glucocorticoids prior to desensitization to minimize airway inflammation and reactivity.",
"     </li>",
"     <li>",
"      Premedications are discussed separately. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Premedications'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients must also be counseled about what to expect during the desensitization protocol. This is critical for reducing patient anxiety and minimizing the likelihood of non-specific, anxiety-related reactions, which range from tingling and numbness of the lips and fingers due to hyperventilation to pruritus, shortness of breath, coughing, nausea, and emesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be informed that desensitization involves administration of a drug to which the patient is known or suspected to be allergic. Accordingly, there is substantial risk of at least a mild allergic reaction. Anaphylaxis is also possible in very sensitive patients or aggressive dose escalations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization is virtually NEVER attempted in patients with histories of reactions involving significant skin desquamation, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, because even small doses of the drug may induce irreversible and potentially fatal recurrent desquamative reactions. Erythema multiforme and diffuse erythroderma with desquamation are other types of reactions for which desensitization should NOT be attempted. Desensitization is also not indicated for serum sickness reactions, nephritis, hepatitis, and other severe non IgE-mediated reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug desensitization carries a risk of acute allergic reactions, which differs with the drug in question and the sensitivity of the individual patient. Most breakthrough reactions are mild and less severe than the patient's initial hypersensitivity reaction. We know of no published fatalities resulting from failed desensitization procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most situations, drug desensitizations should only be performed by allergy specialists trained in the technique. However, certain other specialists may have experience with a specific drug, such as HIV experts desensitizing patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , or oncologists performing desensitization to specific chemotherapy agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Incidence of breakthrough symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin is the drug with which there is the most clinical experience with desensitization. The various protocols reported in the literature are associated with allergic reactions up to 30 percent of the time, although most reactions are mild in severity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/17,20,21\">",
"     17,20,21",
"    </a>",
"    ]. Similar rates are reported with biologic agents that are not foreign proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/22\">",
"     22",
"    </a>",
"    ]. In some studies, desensitization is well tolerated in the majority of patients and the success rate is extremely high in experienced hands [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the author's (MCC) practice, desensitizations for immediate reactions are performed in the hospital setting, with intravenous access and necessary medications, equipment, and personnel necessary to recognize and treat anaphylaxis. Specifically, the supervising allergy specialist is available throughout the procedure. One-to-one nursing with a nurse who has been specifically trained to monitor desensitization protocols and recognize and treat allergic reactions is provided. This nurse has been trained and preauthorized to administer any medications that may be required to treat an allergic reaction, including intramuscular epinephrine for anaphylaxis, so that there will be no delay in treatment if the supervising clinician is not at the bedside when the symptoms begin.",
"   </p>",
"   <p>",
"    If a patient requires recurrent infusions of the drug in question and has successfully undergone uncomplicated desensitization in the hospital, we sometimes carry out repeat desensitizations for that patient in a carefully monitored outpatient setting, such as an infusion center, staffed with a clinician and nurses who have been trained in desensitization, as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, late-occurring reactions have been reported following desensitization in patients who required high-dose or extended-duration therapy, including serum sickness, hemolytic anemia, and nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/5,23\">",
"     5,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TECHNICAL ASPECTS OF DESENSITIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization can be performed by oral, intravenous, or subcutaneous routes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/5,21,24-26\">",
"     5,21,24-26",
"    </a>",
"    ]. The oral route is arguably safest and least expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/5,18\">",
"     5,18",
"    </a>",
"    ], although not always feasible or practical.",
"   </p>",
"   <p>",
"    The route of desensitization does NOT need to be the same as the route of administration. As an example, oral desensitization may be used even if subsequent therapy will be parenteral. Once the patient is successfully desensitized to a given dose, that dose can be administered by any route.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Overview of the technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization is a procedure that alters a patient's immune response to a drug and results in TEMPORARY tolerance, allowing the patient with a drug hypersensitivity reaction (ie, a drug allergy) to receive an uninterrupted course of the medication safely, as stated previously. Once the medication is discontinued, the patient's hypersensitivity to the medication returns.",
"   </p>",
"   <p>",
"    Desensitization is usually performed by starting with a",
"    <span class=\"nowrap\">",
"     1/1000",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/100",
"    </span>",
"    dilution of the drug, which is used to administer an initial dose that is",
"    <span class=\"nowrap\">",
"     1/10,000",
"    </span>",
"    of the full dose (note the distinction between dilution and dose). In exquisitely sensitive patients, an even lower dose that did NOT produce a positive reaction during skin testing can be used instead (for patients who had positive results to higher concentrations on skin testing). Progressively greater doses of a drug are then administered in a stepwise manner, until a full therapeutic dose has been delivered.",
"   </p>",
"   <p>",
"    Typically for IV desensitization, the dose is doubled at intervals of 15 minutes and a continuous infusion is maintained. Increasing the dose faster than doubling is not recommended. For oral desensitization, longer intervals may be required to assure complete absorption before increasing the dose, but long period between doses may allow cellular desensitization to be reversed.",
"   </p>",
"   <p>",
"    Complications of desensitization usually consist of local and mild systemic allergic reactions during the desensitization procedure. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Management of symptoms during desensitization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once the patient is desensitized, the drug is given normally. Maintaining the desensitized state is dependent upon the continuous presence of the drug in the patient's system, so it is important to give doses regularly and on time, so there is no interruption in exposure. In the case of chemotherapy, most agents are given weekly to every three to four weeks, and desensitization has to be repeated each time.",
"   </p>",
"   <p>",
"    Desensitization is also dose dependent, such that a substantial dose increase may result in breakthrough allergic symptoms. Desensitization may also be concentration dependent in some patients, and it is prudent to design the desensitization so that the final (most concentrated) solution is the same concentration at which the drug is normally delivered (for intravenous medications) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific protocols for desensitization by parenteral and oral routes have been published for penicillin, cephalosporins, insulin, and several other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/17,28-31\">",
"     17,28-31",
"    </a>",
"    ]. The tables provide representative protocols for penicillin desensitization that have been published in the literature (",
"    <a class=\"graphic graphic_table graphicRef79351 \" href=\"UTD.htm?30/63/31740\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80213 \" href=\"UTD.htm?7/31/7678\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Standardized protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;At one of the author's (MCC) institution, a 12-step standardized intravenous protocol has been developed and used successfully for immediate hypersensitivity reactions to a variety of drugs (",
"    <a class=\"graphic graphic_table graphicRef52381 \" href=\"UTD.htm?19/20/19790\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75979 \" href=\"UTD.htm?23/17/23838\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/21,22,27,32,33\">",
"     21,22,27,32,33",
"    </a>",
"    ]. This protocol has been used to treat patients with immediate reactions to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Penicillins and other beta-lactams, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      , imipenem, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"     </li>",
"     <li>",
"      Cephalosporins",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      , in patients with severe reactions that have proven refractory to slow infusion and premedication",
"     </li>",
"     <li>",
"      Fluoroquinolones",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       Trimethoprim",
"      </a>",
"     </li>",
"     <li>",
"      Platinum chemotherapy agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Taxane chemotherapy agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       Liposomal doxorubicin",
"      </a>",
"     </li>",
"     <li>",
"      Biologic agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Solutions for the standardized protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 12-step standardized protocol requires three solutions: 1, 2, and 3. A volume of 100 to 250 mL of each solution is needed. Solution 3 is the standard therapeutic solution of the drug as it is normally administered intravenously. Solution 2 is a 10-fold dilution of 3, and solution 1 is a 100-fold dilution of 2 (",
"    <a class=\"graphic graphic_table graphicRef50123 \" href=\"UTD.htm?18/32/18955\">",
"     table 5",
"    </a>",
"    ). The protocol begins with the most dilute solution (solution 1).",
"   </p>",
"   <p>",
"    Exquisitely sensitive patients (ie, those who suffered severe anaphylaxis in response to minute amount of drug) may require a lower starting solution, as mentioned previously. For such patients, we begin with a 1000-fold dilution of 3, and give the drug using a 16-step desensitization protocol (",
"    <a class=\"graphic graphic_table graphicRef65192 \" href=\"UTD.htm?28/63/29694\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Time required",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standardized protocol is completed in approximately six hours, if no pauses for treatment of symptoms are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Premedications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors' approach to premedication depends upon the type of reaction for which desensitization is being performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Desensitization for IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing desensitization for a reaction that is known or believed to be IgE-mediated (eg, many reactions to penicillins or cephalosporins) are usually NOT pretreated with glucocorticoids or antihistamines. Glucocorticoids do not prevent mast cell activation and antihistamines may mask early signs of breakthrough symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Desensitization for non IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose initial reaction is suspected to be non IgE-mediated, such as reactions to taxanes, some other chemotherapy agents, and biologic agents are premedicated with H1 and H2 antihistamines, and sometimes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or glucocorticoids, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      (25 mg intravenously (IV) or orally) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      (25 mg IV or orally), is given 20 minutes before the start of the procedure.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       Ranitidine",
"      </a>",
"      (150 mg orally or 50 mg IV) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"      (20 mg IV or orally), is given 20 minutes before the start of the procedure.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      (325 mg orally), is given to patients with flushing during their initial reaction. This is administered the night before the procedure and again one hour before the start of the procedure. Aspirin has been used successfully with desensitization to platinum chemotherapy agents [",
"      <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      (10 mg orally) is given to patients with respiratory symptoms during their initial reaction. This is administered the night before the procedure and again one hour before the start of the procedure. Montelukast has been used successfully with desensitization to platinum chemotherapy agents [",
"      <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When desensitizing to chemotherapy or biologic agents, any premedications (such as glucocorticoids) that are routinely used for patients receiving the drug under normal circumstances should be incorporated into the planned premedications as well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Administering the standardized protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient has been premedicated (if appropriate), the protocol is begun with the most dilute solution, solution 1, as shown in the figure (",
"    <a class=\"graphic graphic_table graphicRef52381 \" href=\"UTD.htm?19/20/19790\">",
"     table 3",
"    </a>",
"    ). Step 1 consists of solution 1, administered at a rate of 2",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for 15 minutes. The infusion rate is increased to 5",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for step 2, 10",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for step 3, and 20",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for step 4. Solution 1 is then replaced by solution 2, which is given in the same manner, followed by solution 3. The final step, step 12, is longer in duration and delivers the remainder of the solution required to reach a full therapeutic dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management of symptoms during desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the success of desensitization depends upon the comfort and experience of the supervising allergy specialist in managing breakthrough reactions. Nearly all symptoms can be effectively managed, and the protocol subsequently completed.",
"   </p>",
"   <p>",
"    If symptoms arise during the procedure, the infusion should be halted temporarily until symptoms have resolved. Sometimes, symptoms will resolve with stopping the infusion alone, but if symptoms are significant, do not appear to be resolving spontaneously, or are worsening, then treatment should be administered. Treatment usually consists of antihistamines for pruritus or urticaria, inhaled bronchodilators for chest tightness or wheezing, or epinephrine for uncommon systemic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     When to abort a desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A desensitization should be aborted if a patient develops hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laryngeal edema that is not immediately responsive to intramuscular epinephrine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Adjusting the protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once breakthrough symptoms have resolved or been treated, the protocol is resumed by repeating the step at which the reaction occurred. We do not back up and repeat earlier steps.",
"   </p>",
"   <p>",
"    We have noticed that breakthrough reactions are more common at certain points in the protocol. During desensitizations to chemotherapy agents and antibiotics, breakthrough symptoms occur most often at step 12, whereas with biologic agents, patients may react at different steps (steps 9 to 12) during infusion of the most concentrated solution.",
"   </p>",
"   <p>",
"    If the patient experienced a breakthrough reaction and needs repeat desensitization in the future (as is often the case in patients requiring chemotherapy) we then modify the protocol to add an intermediate step before the one at which symptoms occurred. As an example, if a patient reacted during the first few minutes of step 12, we would then add an extra step before that one and this modified protocol is used for all the patient's future desensitizations. Usually, we increase the infusion rate less than twofold to create an extra step.",
"   </p>",
"   <p>",
"    If a patient experienced no symptoms during the final step of the initial desensitization, then the rate of infusion during the final step may be accelerated for repeat desensitizations. The maximum rate of infusion should be that rate at which the drug is normally given. This modification can be helpful by reducing the time required to perform the desensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Duration of effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization induces a temporary state of clinical tolerance. After a patient has been desensitized and treated with a course of the drug, the allergic sensitivity to the drug will return shortly after the medication is cleared from the bloodstream. The patient must be counseled that desensitization is NOT A CURE for drug allergy. They must continue to avoid the drug after treatment is completed, and repeat desensitization must be performed if the drug is required again.",
"   </p>",
"   <p>",
"    After the drug is discontinued, the desensitized state dissipates over days to weeks. In most instances, the patient will remain desensitized for a minimum of 24 to 48 hours, so that missing a single dose does not usually necessitate repeat desensitization.",
"   </p>",
"   <p>",
"    The speed with which the patient's sensitivity to the medicine returns is dependent upon multiple variables, including the half-life of the drug, the formation of drug-containing immune complexes that can delay clearance of the drug, the degree to which the drug binds to serum proteins or other tissues, and the patient's renal function. In most cases, return of the patient's sensitivity is so sufficiently difficult to predict that repeat desensitization is usually performed if more than 48 hours have elapsed since the last dose.",
"   </p>",
"   <p>",
"    If a patient had positive immediate skin tests to the drug prior to desensitization, which then reverted to negative after the desensitization, it has been our experience that the skin test may be used to follow the patient's status. Desensitization is not needed as long as the skin test remains negative.",
"   </p>",
"   <p>",
"    A few reports have described the long-term maintenance of desensitization by chronic daily oral administration for select patients in whom recurrent infections necessitated intermittent antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/5,35\">",
"     5,35",
"    </a>",
"    ] or for whom occupational exposure was unavoidable and disabling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/7\">",
"     7",
"    </a>",
"    ]. However, published clinical experience with chronic desensitization is very limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall success rate of desensitization depends upon the protocol used, the sensitivity of the patient, and the expertise of the supervising clinician in managing any symptoms that occur and adjusting the procedure accordingly.",
"   </p>",
"   <p>",
"    IgE-mediated reactions, such as those to beta lactam antibiotics and platinum-based chemotherapy agents, have very high rates of success. In experienced hands, virtually all of these desensitizations are successful.",
"   </p>",
"   <p>",
"    In most cases, patients who experience breakthrough reactions during initial desensitizations, display fewer symptoms upon repeat desensitization, using the approach described above for modifying the protocol. However, there may be an important subset of patients in which this is not the case. In a study of desensitizations to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , a small number of patients undergoing desensitization more than eight times appeared to have a resurgence in their sensitivity to the drug during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/62/29672/abstract/22\">",
"     22",
"    </a>",
"    ]. We have also noticed this in a small number of patients requiring repeated desensitizations to one chemotherapy agent or antibiotic. This phenomenon requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     APPLICATION TO OTHER TYPES OF DRUG ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term desensitization is used somewhat loosely in the medical literature. Various protocols have been used to achieve drug tolerance in patients with delayed hypersensitivity reactions to drugs, although the time course of reintroduction may extend over days or even weeks. Desensitization for delayed reactions to sulfonamides are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link\">",
"     \"Sulfonamide allergy in non HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned earlier, clinical desensitization is also possible for patients with various non IgE-mediated reactions to NSAIDs, and these protocols differ significantly from the standardized protocol presented above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=see_link\">",
"     \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=see_link\">",
"       \"Patient information: Drug allergy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desensitization involves the administration of a drug beginning with very small doses and gradually increasing in a stepwise manner until a full therapeutic dose is reached. Desensitization alters a patient's adverse immune response to a drug and results in TEMPORARY tolerance, allowing the patient with a hypersensitivity reaction to receive an uninterrupted course of the medication safely. Once the medication is discontinued, the patient's hypersensitivity to the medication returns. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Proposed mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The World Allergy Organization (WAO) has defined immediate hypersensitivity reactions as hypersensitivity reactions that begin within one hour of exposure to the culprit drug. The drug desensitization approach described in this topic review can be applied to patients with either IgE-mediated or non IgE-mediated immediate hypersensitivity reactions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immediate drug reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications and patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Desensitization is NOT effective, and may be dangerous (even fatal) in patients with Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, diffuse erythroderma with desquamation, and serum sickness reactions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premedications are administered before some, but not all, desensitizations, depending on the mechanism that is believed to underlie the reaction. In addition, any premedications that are normally given before administration in a patient without hypersensitivity should also be given before desensitization. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Premedications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The success rate of drug desensitization is very high when performed by experienced drug allergy experts. Patients may experience mild breakthrough reactions during as many as 30 percent of desensitizations, and the clinician's experience in managing these is critical. Breakthrough symptoms are managed by stopping the infusion temporarily, administering specific treatments, and restarting the protocol again at the step that elicited symptoms. The protocol should be adjusted to advance through the problematic step more gradually if it is to be performed again in the same patient. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Technical aspects of desensitization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/1\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/2\">",
"      Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002; 20:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/3\">",
"      Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998; 90:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/4\">",
"      Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol 1982; 69:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/5\">",
"      Stark BJ, Earl HS, Gross GN, et al. Acute and chronic desensitization of penicillin-allergic patients using oral penicillin. J Allergy Clin Immunol 1987; 79:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/6\">",
"      Graybill JR, Sande MA, Reinarz JA, Shapiro SR. Controlled penicillin anaphylaxis leading to desensitization. South Med J 1974; 67:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/7\">",
"      Naclerio R, Mizrahi EA, Adkinson NF Jr. Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin. J Allergy Clin Immunol 1983; 71:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/8\">",
"      Sobotka AK, Dembo M, Goldstein B, Lichtenstein LM. Antigen-specific desensitization of human basophils. J Immunol 1979; 122:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/9\">",
"      Pruzansky JJ, Patterson R. Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization. Immunology 1988; 65:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/10\">",
"      MacGlashan D Jr, Lichtenstein LM. Basic characteristics of human lung mast cell desensitization. J Immunol 1987; 139:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/11\">",
"      Paolini R, Numerof R, Kinet JP. Phosphorylation/dephosphorylation of high-affinity IgE receptors: a mechanism for coupling/uncoupling a large signaling complex. Proc Natl Acad Sci U S A 1992; 89:10733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/12\">",
"      Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005; 94:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/13\">",
"      Macglashan D, Miura K. Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol 2004; 114:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/14\">",
"      Odom S, Gomez G, Kovarova M, et al. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J Exp Med 2004; 199:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/15\">",
"      Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 2005; 138:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/16\">",
"      Pienkowski MM, Kazmier WJ, Adkinson NF Jr. Basophil histamine release remains unaffected by clinical desensitization to penicillin. J Allergy Clin Immunol 1988; 82:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/17\">",
"      Wendel GD Jr, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/18\">",
"      Chisholm CA, Katz VL, McDonald TL, Bowes WA Jr. Penicillin desensitization in the treatment of syphilis during pregnancy. Am J Perinatol 1997; 14:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/19\">",
"      Ziaya PR, Hankins GD, Gilstrap LC 3rd, Halsey AB. Intravenous penicillin desensitization and treatment during pregnancy. JAMA 1986; 256:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/20\">",
"      Macy E. Penicillin skin testing in pregnant women with a history of penicillin allergy and group B streptococcus colonization. Ann Allergy Asthma Immunol 2006; 97:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/21\">",
"      Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 2009; 29:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/22\">",
"      Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/23\">",
"      Sullivan TJ, Yecies LD, Shatz GS, et al. Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics. J Allergy Clin Immunol 1982; 69:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/24\">",
"      Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/25\">",
"      Gruchalla RS. Acute drug desensitization. Clin Exp Allergy 1998; 28 Suppl 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/26\">",
"      Moyes V, Driver R, Croom A, et al. Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabet Med 2006; 23:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/27\">",
"      Legere HJ 3rd, Palis RI, Rodriguez Bouza T, et al. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009; 8:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/28\">",
"      Burrows JA, Toon M, Bell SC. Antibiotic desensitization in adults with cystic fibrosis. Respirology 2003; 8:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/29\">",
"      Wilson DL, Owens RC Jr, Zuckerman JB. Successful meropenem desensitization in a patient with cystic fibrosis. Ann Pharmacother 2003; 37:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/30\">",
"      Win PH, Brown H, Zankar A, et al. Rapid intravenous cephalosporin desensitization. J Allergy Clin Immunol 2005; 116:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/31\">",
"      Ghosal S, Taylor CJ. Intravenous desensitization to ceftazidime in cystic fibrosis patients. J Antimicrob Chemother 1997; 39:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/32\">",
"      Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/33\">",
"      Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010; 65:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/34\">",
"      Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 2009; 102:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/62/29672/abstract/35\">",
"      Brown LA, Goldberg ND, Shearer WT. Long-term ticarcillin desensitization by the continuous oral administration of penicillin. J Allergy Clin Immunol 1982; 69:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2071 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-ADE281C057-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29672=[""].join("\n");
var outline_f28_62_29672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMEDIATE DRUG REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IgE-mediated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Non IgE-mediated",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROPOSED MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS AND PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Preparing the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Incidence of breakthrough symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunologic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TECHNICAL ASPECTS OF DESENSITIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Route of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Overview of the technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Standardized protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Solutions for the standardized protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Time required",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Premedications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Desensitization for IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Desensitization for non IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Administering the standardized protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management of symptoms during desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - When to abort a desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Adjusting the protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Duration of effect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      APPLICATION TO OTHER TYPES OF DRUG ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2071\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2071|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/63/31740\" title=\"table 1\">",
"      Beta-lactam oral desensitization protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/31/7678\" title=\"table 2\">",
"      PCN desens IV pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/20/19790\" title=\"table 3\">",
"      Desens 12step 250mL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/17/23838\" title=\"table 4\">",
"      Desens biologics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/32/18955\" title=\"table 5\">",
"      Desens sol std",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/63/29694\" title=\"table 6\">",
"      Desens 16step",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=related_link\">",
"      Diagnostic challenge and desensitization protocols for NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=related_link\">",
"      Patient information: Drug allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_62_29673="Thalidomide: Drug information";
var content_f28_62_29673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thalidomide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/48/44805?source=see_link\">",
"    see \"Thalidomide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/42/42664?source=see_link\">",
"    see \"Thalidomide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thalomid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Thalomid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F226500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiogenesis Inhibitor;",
"     </li>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Immunomodulator, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F226484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cutaneous ENL:",
"     </b>",
"     Oral: Initial: 100-300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjustments to initial dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients weighing &lt;50 kg: Initiate at lower end of the dosing range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe cutaneous reaction or patients previously requiring high dose may be initiated at 400 mg daily; doses may be divided, but taken 1 hour after meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Duration and tapering/maintenance:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: Dosing should continue until active reaction subsides (usually at least 2 weeks), then tapered in 50 mg decrements every 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients who flare during tapering or with a history of requiring prolonged maintenance should be maintained on the minimum dosage necessary to control the reaction. Efforts to taper should be repeated every 3-6 months, in decrements of 50 mg every 2-4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Details concerning dosing for multiple myeloma with combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg once daily at bedtime (in combination with dexamethasone 40 mg daily on days 1-4, 9-12, and 17-20 of a 28-day treatment cycle)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In combination with bortezomib and dexamethasone (unlabeled combination):  Induction therapy: 100 mg once daily for the first 14 days, then 200 mg once daily for 3 (21-day) cycles (Cavo, 2010)",
"     <b>",
"      or",
"     </b>",
"     100 mg once daily for up to 8 (21-day) cycles (Kaufman, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In combination with melphalan and prednisone (unlabeled combination in U.S.): 200-400 mg once daily (Facon, 2007)",
"     <b>",
"      or",
"     </b>",
"     100 mg once daily (Palumbo, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Adults &ge;65 years: 200 mg once daily; maximum: 12 six-week cycles (in combination with melphalan and prednisone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Multiple myeloma, maintenance (following autologous stem cell transplant; unlabeled use):",
"     </i>",
"     Oral: 200 mg once daily starting 3-6 months after transplant; continue until disease progression or unacceptable toxicity (Brinker, 2006) or 100 mg once daily starting 42-60 days following transplant; increase to 200 mg once daily after 2 weeks if tolerated; continue for up to 12 months (in combination with prednisolone) (Spencer, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AIDS-related aphthous stomatitis (unlabeled use):",
"     </b>",
"     Oral: 200 mg once daily at bedtime for up to 8 weeks, if no response, then 200 mg twice daily for 4 weeks (Jacobson, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic graft-versus-host disease (refractory), treatment (unlabeled second-line use; optimum dose  not determined):",
"     </b>",
"     Oral: Initial: 100 mg once daily at bedtime, with dose escalation up to 400 mg daily in 3-4 divided doses (Wolff, 2010)",
"     <b>",
"      or",
"     </b>",
"     Initial: 50-100 mg 3 times daily; maximum dose: 600-1200 mg daily (Kulkarni, 2003)",
"     <b>",
"      or",
"     </b>",
"     200 mg 4 times daily (dose adjusted to goal thalidomide concentration of &ge;5 mcg/mL 2 hours postdose) (Vogelsang, 1992)",
"     <b>",
"      or",
"     </b>",
"     100-300 mg 4 times daily (Parker, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Crohn&rsquo;s disease, refractory (unlabeled use):",
"     </b>",
"     Oral: 50-100 mg once daily at bedtime (Vasiliauskas, 1999)",
"     <b>",
"      or",
"     </b>",
"     200-300 mg once daily at bedtime (Ehrenpreis, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic light chain amyloidosis (unlabeled use):",
"     </b>",
"     Oral: 200 mg once daily (starting dose 50-100 mg once daily; titrate at 4-week intervals) in combination with cyclophosphamide and dexamethasone (Wechalekar, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Waldenstr&ouml;m&rsquo;s macroglobulinemia (unlabeled use):",
"     </b>",
"     Oral: 200 mg once daily for up to 52 weeks (in combination with rituximab) (Treon, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10927005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/42/42664?source=see_link\">",
"      see \"Thalidomide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cutaneous ENL:",
"     </b>",
"     Children &ge;12 years: Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic graft-versus-host disease (refractory), treatment (unlabeled second-line use; limited data):",
"     </b>",
"     Children &ge;3 years: Oral: 3 mg/kg 4 times daily (dose adjusted to goal thalidomide concentration of &ge;5 mcg/mL 2 hours postdose) (Vogelsang, 1992)",
"     <b>",
"      or",
"     </b>",
"     Initial: 3-6 mg/kg/day in 2-4 divided doses; target dose 12 mg/kg/day; Maximum daily dose: 800 mg (Rovelli, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F226485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12926530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No adjustment is required for patients with renal impairment and on dialysis (per manufacturer). In a study of 6 patients with end-stage renal disease on dialysis, although clearance was increased by dialysis, a supplemental dose was not needed (Eriksson, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Multiple myeloma:",
"     </i>",
"     An evaluation of 29 newly-diagnosed myeloma patients with renal failure (serum creatinine &ge;2 mg/dL) treated with thalidomide and dexamethasone (some also received cyclophosphamide) found that toxicities and efficacy were similar to patients with normal renal function (Seol, 2010). A study evaluating induction therapy with thalidomide and dexamethasone in 31 newly-diagnosed myeloma patients with renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute), including 16 patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) and 7 patients on chronic hemodialysis found that toxicities were similar to patients without renal impairment and that thalidomide and dexamethasone could be administered safely (Tosi, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12926531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, thalidomide does not appear to undergo significant hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F10927004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      ANC &le;750/mm",
"      <sup>",
"       3",
"      </sup>",
"      :",
"     </b>",
"     Withhold treatment if clinically appropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Constipation, oversedation, peripheral neuropathy: Temporarily withhold or continue with a reduced dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     ANC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold melphalan and prednisone for 1 week; resume melphalan and prednisone after 1 week if ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     if ANC 1000-1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     reduce melphalan dose by 50%",
"     <b>",
"      or",
"     </b>",
"     if ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     adjust chemotherapy dose based on clinical status of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Constipation, oversedation: Temporarily withhold thalidomide treatment or continue with a reduced dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Peripheral neuropathy, Grade 1 (paresthesia, weakness and/or loss of reflexes) without loss of function): Evaluate patient and consider dose reduction with worsening of symptoms; symptom improvement may not follow dose reduction, however.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Peripheral neuropathy, Grade 2 (interferes with function but not with daily activities), Grade 3 (interferes with daily activities), or Grade 4 (disabling neuropathy): Discontinue thalidomide treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Thromboembolic events: Withhold therapy and initiate standard anticoagulant treatment;  may resume thalidomide therapy at original dose following stabilization of patient and resolution of thromboembolic event; maintain anticoagulant treatment for duration of thalidomide therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Unlabeled recommendation (Richardson, 2012):",
"     </i>",
"     Peripheral neuropathy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Grade 1: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Grade 2: Temporarily interrupt therapy; once resolved to &le; grade 1, resume therapy with a 50% dosage reduction (if clinically appropriate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Grade 3 or higher: Discontinue therapy",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thalomid&reg;: 50 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      U.S.:",
"     </b>",
"     As a requirement of the REMS program, access to this medication is restricted. Thalidomide is approved for marketing only under a special distribution program, the Thalomid REMS&trade;  (www.celgeneriskmanagment.com or 1-888-423-5436), which has been approved by the FDA. Prescribers, patients, and pharmacies  must be certified with the program to prescribe or dispense thalidomide. No more than a 4-week supply should be dispensed. Blister packs should be dispensed intact (do not repackage capsules). Prescriptions must be filled within 7 days (for females of reproductive potential) or within 30 days (for all other patients) after authorization number obtained. Subsequent prescriptions may be filled only if fewer than 7 days of therapy remain on the previous prescription. A new prescription is required for further dispensing (a telephone prescription may not be accepted.) Pregnancy testing is required for females of childbearing potential.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Canada:",
"     </b>",
"     Access to thalidomide is restricted through a controlled distribution program called RevAid&reg;. Only physicians and pharmacists enrolled in this program are authorized to prescribe or dispense thalidomide. Patients must be enrolled in the program by their physicians. Further information is available at www.RevAid.ca or by calling 1-888-738-2431.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10523386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222363.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222363.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F226461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     Avoid extensive handling of capsules; capsules should remain in blister pack until ingestion. If exposed to the powder content from broken capsules or body fluids from patients receiving thalidomide, the exposed area should be washed with soap and water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     U.S. labeling: Administer orally with water, preferably at bedtime once daily on an empty stomach, at least 1 hour after the evening meal. Doses &gt;400 mg/day may be given in 2-3 divided doses  at least 1 hour after meals. For missed doses, if &lt;12 hours patient may receive dose; if &gt;12 hours wait till next dose due.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling: Administer orally as a single dose at the same time each day; may be taken without regard to meals. May be administered at bedtime to decrease somnolence. Capsules should be swallowed whole, preferably with water.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F226460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of newly-diagnosed multiple myeloma; treatment and maintenance of cutaneous manifestations of erythema nodosum leprosum (ENL)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F226496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory Crohn's disease; treatment of chronic graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation; AIDS-related aphthous stomatitis; Waldenstr&ouml;m's macroglobulinemia; maintenance therapy of multiple myeloma (following autologous stem cell transplant); systemic light chain amyloidosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thalidomide may be confused with flutamide, lenalidomide, pomalidomide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thalomid&reg; may be confused with thiamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Thalomid [U.S., Canada] may be confused with Thilomide brand name for lodoxamide [Greece, Turkey]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F226498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (57%), thrombosis/embolism (23%; grade 3: 13%, grade 4: 9%), hypotension (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (79%; grade 3: 14%, grade 4: 3%), somnolence (36% to 38%), dizziness (4% to 20%), sensory neuropathy (54%), confusion (28%), anxiety/agitation (9% to 26%), fever (19% to 23%), motor neuropathy (22%), headache (13% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash/desquamation (21% to 30%; grade 3: 4%), dry skin (21%), maculopapular rash (4% to 19%), acne (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (72%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (3% to 55%), nausea (4% to 28%), anorexia (3% to 28%), weight loss (23%), weight gain (22%), diarrhea (4% to 19%), oral moniliasis (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (17% to 35%), neutropenia (31%), anemia (6% to 13%), lymphadenopathy (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (3% to 25%), bilirubin increased (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness (40%), tremor (4% to 26%), weakness (6% to 22%), myalgia (17%), paresthesia (6% to 16%), arthralgia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (42%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (3% to 8%), facial edema (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (9%), nervousness (3% to 9%), malaise (8%), vertigo (8%), pain (3% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (fungal 4% to 9%), pruritus (3% to 8%), nail disorder (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperlipemia (6% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (8% to 9%), flatulence (8%), tooth pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (3% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs abnormal (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuropathy (8%), back pain (4% to 6%), neck pain (4%), neck rigidity (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria (3% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (4% to 8%), rhinitis (4%), sinusitis (3% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (6% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (limited to important or life-threatening): Acute renal failure, alkaline phosphatase increased, ALT increased, amenorrhea, angioedema, aphthous stomatitis, arrhythmia, atrial fibrillation, bile duct obstruction, bradycardia, BUN increased, carpal tunnel, CML, creatinine clearance decreased, creatinine increased, deafness, depression, diplopia, dysesthesia, ECG abnormalities, enuresis, eosinophilia, epistaxis, erythema multiforme, erythema nodosum, erythroleukemia, exfoliative dermatitis, febrile neutropenia, foot drop, galactorrhea, granulocytopenia, gynecomastia, hearing loss, hepatomegaly, Hodgkin's disease, hypercalcemia, hyper-/hypokalemia, hypersensitivity, hypertension, hyper-/hypothyroidism, hypersensitivity, hyperuricemia, hypomagnesemia, hyponatremia, hypoproteinemia, intestinal obstruction, intestinal perforation, interstitial pneumonitis, LDH increased, lethargy, leukocytosis, loss of consciousness, lymphedema, lymphopenia, mental status changes, metrorrhagia, MI, myxedema, nystagmus, oliguria, orthostatic hypotension, pancytopenia, paresthesia, petechiae, peripheral neuritis, photosensitivity, pleural effusion, prothrombin time changes, psychosis, pulmonary embolus, pulmonary hypertension, purpura, Raynaud's syndrome, renal failure, seizure, sepsis, septic shock, sexual dysfunction, sick sinus syndrome, status epilepticus, Stevens-Johnson syndrome, stomach ulcer, stupor, suicide attempt, syncope, tachycardia, thrombocytopenia, toxic epidermal necrolysis, tumor lysis syndrome, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F226464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thalidomide or any component of the formulation; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to lenalidomide; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F226446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May cause neutropenia; avoid initiating therapy if ANC &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; monitor blood counts. Persistent neutropenia may require treatment interruption. Anemia and thrombocytopenia have also been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: May cause bradycardia; use with caution in patients with cardiovascular disease. May require dose reduction or  discontinuation. Use caution when administering with concomitant medications which may decrease heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause dizziness, drowsiness, and/or somnolence; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving). Avoid concomitant medications which may exacerbate these symptoms; dose reductions may be necessary for excessive drowsiness or somnolence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation: Constipation may commonly occur. May require treatment interruption or dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (may be fatal); withhold therapy and evaluate with skin rashes; permanently discontinue if rash is exfoliative, purpuric, bullous or if SJS or TEN is suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity, including erythematous macular rash, possibly associated with fever, tachycardia and hypotension has been reported. May require treatment interruption for severe reactions; discontinue if recurs with rechallenge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients who would not tolerate transient hypotensive episodes. When arising from a recumbent position, advise patients to sit upright for a few minutes prior to standing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Associated with the development of peripheral neuropathy, which may be irreversible; generally occurs following chronic use (over months), but may occur with short-term use; onset may be delayed. Use caution with other medications which may also cause peripheral neuropathy. Monitor for signs/symptoms of neuropathy monthly for the first 3 months of therapy and regularly thereafter. Electrophysiological testing may be considered at baseline and every 6 months to detect asymptomatic neuropathy. Consider immediate discontinuation (if clinically appropriate) in patients who develop neuropathy. Reinitiate therapy only if neuropathy returns to baseline; may require dosage reduction or permanent discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Seizures have been reported in postmarketing data; use caution in patients with a history of seizures, concurrent therapy with drugs which alter seizure threshold, or conditions which predispose to seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: Associated with an increased risk for venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in multiple myeloma patients; the risk is increased when used in combination with dexamethasone. Monitor for signs and symptoms of thromboembolism (shortness of breath, chest pain, or arm or leg swelling); and instruct patients to seek prompt medical attention with development of these symptoms. Patients at risk may benefit from prophylactic anticoagulation.",
"     </b>",
"     The NCCN multiple myeloma guidelines (v.1.2013) recommend anticoagulant prophylaxis with thalidomide-based therapy. Anticoagulant prophylaxis should be individualized and selected based on the venous thromboembolism risk of the combination treatment regimen, using the safest and easiest to administer (Palumbo, 2008). The Canadian labeling recommends anticoagulant prophylaxis for at least the first 5 months of thalidomide-based therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Patients with a high tumor burden may be at risk for tumor lysis syndrome; monitor closely; institute appropriate management for hyperuricemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Certain adverse reactions (constipation, fatigue, weakness, nausea, hypokalemia, hyperglycemia, DVT, pulmonary embolism, atrial fibrillation) are more likely in elderly patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV-infected patients: Associated with increased viral loads in studies conducted prior to the use of highly active antiretroviral therapy. Monitor viral load after the first and third months of therapy, and every 3 months thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Thalidomide may cause severe birth defects or embryo-fetal death if taken during pregnancy. Thalidomide cannot be used in women who are pregnant or may become pregnant during therapy as even a single dose may cause birth defects. In order to decrease the risk of fetal exposure, thalidomide is available only through a special restricted distribution program (Thalomid REMS&trade;).",
"     </b>",
"     Use is contraindicated in women who are or may become pregnant. Pregnancy must be excluded prior to therapy initiation with 2 negative pregnancy tests. Women of reproductive potential must avoid pregnancy 4 weeks prior to therapy, during therapy, during therapy interruptions, and for &ge;4 weeks after therapy is discontinued; two reliable methods of birth control, or abstinence from heterosexual intercourse, must be used. Males taking thalidomide (even those vasectomized) must use a latex or synthetic condom during any sexual contact with women of childbearing potential and for up to 28 days following discontinuation of therapy. Males taking thalidomide must not donate sperm. Some forms of contraception may not be appropriate in certain patients. An intrauterine device (IUD) or implantable contraceptive may increase the risk of infection or bleeding; estrogen containing products may increase the risk of thromboembolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donation: Patients should not donate blood during thalidomide treatment and for 1 month after therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Thalidomide should only be prescribed to patients who can understand and comply with the conditions of the Thalomid REMS&trade; program.",
"     </b>",
"     . Prescribers, patients, and pharmacies must be certified with the program to prescribe or dispense thalidomide.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): May enhance the dermatologic adverse effect of Thalidomide. Dexamethasone (Systemic) may enhance the thrombogenic effect of Thalidomide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pamidronate: Thalidomide may enhance the nephrotoxic effect of Pamidronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zoledronic Acid: Thalidomide may enhance the adverse/toxic effect of Zoledronic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F226477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid cat's claw and echinacea (have immunostimulant properties; consider therapy modifications).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F226466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Thalidomide may cause severe birth defects or embryo-fetal death if taken during pregnancy. Thalidomide cannot be used in women who are pregnant or may become pregnant during therapy as even a single dose may cause birth defects. In order to decrease the risk of fetal exposure, thalidomide is available only through a special restricted distribution program (Thalomid REMS&trade;).",
"     </b>",
"     Reproduction studies in animals and data from pregnant women have shown evidence of fetal abnormalities; use is contraindicated in women who are or may become pregnant. Anomalies observed in humans include amelia, phocomelia, bone defects, ear and eye abnormalities, facial palsy, congenital heart defects, urinary and genital tract malformations; mortality in ~40% of infants at or shortly after birth has also been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Women of reproductive potential must avoid pregnancy 4 weeks prior to therapy, during therapy, during therapy interruptions, and for &ge;4 weeks after therapy is discontinued.  Two forms of effective contraception or total abstinence from heterosexual intercourse must be used by females who are not infertile or who have not had a hysterectomy.  A negative pregnancy test (sensitivity of at least 50 mIU/mL) 10-14 days prior to therapy, within 24 hours prior to beginning therapy, weekly during the first 4 weeks, and every 4 weeks (every 2 weeks for women with irregular menstrual cycles) thereafter is required for women of childbearing potential. Thalidomide must be immediately discontinued for a missed period, abnormal pregnancy test or abnormal menstrual bleeding; refer patient to a reproductive toxicity specialist if pregnancy occurs during treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Females of reproductive potential must also avoid contact with thalidomide capsules.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Thalidomide is also present in the semen of males. Males (even those vasectomized) must use a latex or synthetic condom during any sexual contact with women of childbearing potential and for up to 28 days following discontinuation of therapy. Males taking thalidomide must not donate sperm.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     The parent or legal guardian for patients between 12-18 years of age must agree to ensure compliance with the required guidelines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     If pregnancy occurs during treatment, thalidomide must be immediately discontinued and the patient referred to a reproductive toxicity specialist. Any suspected fetal exposure to thalidomide must be reported to the FDA via the MedWatch program (1-800-FDA-1088) and to Celgene Corporation (1-888-423-5436). In Canada, thalidomide is available only through a restricted-distribution program called RevAid&reg; (1-888-738-2431).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F226489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F226467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if thalidomide is excreted in breast milk. Due to the potential for serious adverse reactions in the infant, a decision should be made to discontinue nursing or discontinue treatment with thalidomide, taking into account the importance of treatment to the mother. Use in breast-feeding women is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F226468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at least 1 hour after the evening meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Thalomid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (28): $5101.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (28): $8281.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (28): $8854.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (28): $9428.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F226454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelets; thyroid function tests (TSH at baseline then every 2-3 months during thalidomide treatment [Hamnvik, 2011]).  In HIV-seropositive patients: viral load after 1 and 3 months, then every 3 months. Pregnancy testing (sensitivity of at least 50 mIU/mL) is required within 24 hours prior to initiation of therapy, weekly during the first 4 weeks, then every 4 weeks in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles. Signs of neuropathy monthly for the first 3 months, then periodically during treatment; consider monitoring of sensory nerve application potential amplitudes (at baseline and every 6 months) to detect asymptomatic neuropathy. Monitor for signs and symptoms of thromboembolism (shortness of breath, chest pain, arm/leg swelling).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F226458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Graft-vs-host disease: Therapeutic plasma thalidomide levels are 5-8 mcg/mL, although it has been suggested that lower plasma levels (0.5-1.5 mcg/mL) may be therapeutic; peak serum thalidomide level after a 200 mg dose: 1.8 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F226469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Inmunoprin (CN, CO, EC, UY);",
"     </li>",
"     <li>",
"      Thado (MY, TW);",
"     </li>",
"     <li>",
"      Thalix (IN, PH);",
"     </li>",
"     <li>",
"      Thalomid (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F226445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunomodulatory and antiangiogenic characteristics; immunologic effects may vary based on conditions; may suppress excessive tumor necrosis factor-alpha production in patients with ENL, yet may increase plasma tumor necrosis factor-alpha levels in HIV-positive patients. In multiple myeloma, thalidomide is associated with an increase in natural killer cells and increased levels of interleukin-2 and interferon gamma. Other proposed mechanisms of action include suppression of angiogenesis, prevention of free-radical-mediated DNA damage, increased cell mediated cytotoxic effects, and altered expression of cellular adhesion molecules.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F226463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow, good",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55% to 66%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Nonenzymatic hydrolysis in plasma; forms multiple metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Capsule: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5.5-7.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (92%; &lt;41% as unchanged drug); feces (&lt;2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antonioli E, Nozzoli C, Gianfaldoni G, et al, &ldquo;Pulmonary Hypertension Related to Thalidomide Therapy in Refractory Multiple Myeloma,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      ,  2005, 16(11):1849-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/16012178/pubmed\" id=\"16012178\" target=\"_blank\">",
"        16012178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brinker BT, Walker EK, Leong T, et al, &ldquo;Maintenance Therapy With Thalidomide Improves Overall Survival After Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(10):2171-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/16598756/pubmed\" id=\"16598756\" target=\"_blank\">",
"        16598756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Browne PV, Weisdorf DJ, DeFor T, et al, &ldquo;Response to Thalidomide Therapy in Refractory Chronic Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2000, 26(8):865-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/11081386/pubmed\" id=\"11081386\" target=\"_blank\">",
"        11081386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cavo M, Tacchetti P, Patriarca F, et al, &ldquo;Bortezomib With Thalidomide Plus Dexamethasone Compared With Thalidomide Plus Dexamethasone as Induction Therapy Before, and Consolidation Therapy After, Double Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Randomised Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9758):2075-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/21146205/pubmed\" id=\"21146205\" target=\"_blank\">",
"        21146205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos MA, Terpos E, Chanan-Khan A, et al, &ldquo;Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(33):4976-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/20956629/pubmed\" id=\"20956629\" target=\"_blank\">",
"        20956629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ehrenpreis ED, Kane SV, Cohen LB, et al, &ldquo;Thalidomide Therapy for Patients With Refractory Crohn's Disease: An Open-Label Trial,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1999, 117(6):1271-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/10579967/pubmed\" id=\"10579967\" target=\"_blank\">",
"        10579967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson T, H&ouml;glund P, Turesson I, et al, &ldquo;Pharmacokinetics of Thalidomide in Patients With Impaired Renal Function and While On and Off Dialysis,&rdquo;",
"      <i>",
"       J Pharm Pharmacol",
"      </i>",
"      , 2003, 55(12):1701-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/14738599/pubmed\" id=\"14738599\" target=\"_blank\">",
"        14738599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Facon T, Mary JY, Hulin C, et al, \"Melphalan and Prednisone Plus Thalidomide Versus Melphalan and Prednisone Alone or Reduced-Intensity Autologous Stem Cell Transplantation in Elderly Patients With Multiple Myeloma (IFM 99-06): A Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9594):1209-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/17920916/pubmed\" id=\"17920916\" target=\"_blank\">",
"        17920916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamuryudan V, Mat C, Saip S, et al, &ldquo;Thalidomide in the Treatment of the Mucocutaneous Lesions of the Beh&ccedil;et Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1998, 128(6):443-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/9499327/pubmed\" id=\"9499327\" target=\"_blank\">",
"        9499327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hulin C, Facon T, Rodon P, et al, &ldquo;Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(22):3664-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/19451428/pubmed\" id=\"19451428\" target=\"_blank\">",
"        19451428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JM, Greenspan JS, Spritzler J, et al, &ldquo;Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients With Human Immunodeficiency Virus Infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(21):1487-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/9154767/pubmed\" id=\"9154767\" target=\"_blank\">",
"        9154767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman JL, Nooka A, Vrana M, et al, &ldquo;Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients With Symptomatic Multiple Myeloma: A Retrospective Study,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2010, 116(13):3143-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/20564642/pubmed\" id=\"20564642\" target=\"_blank\">",
"        20564642",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kulkarni S, Powles R, Sirohi B, et al,  &ldquo;Thalidomide After Allogeneic Haematopoietic Stem Cell Transplantation: Activity in Chronic But Not in Acute Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2003, 32(2):165-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/12838281/pubmed\" id=\"12838281\" target=\"_blank\">",
"        12838281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kyle RA and Rajkumar SV, &ldquo;Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(18): 1860-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/15575057/pubmed\" id=\"15575057\" target=\"_blank\">",
"        15575057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lokhorst HM, van der Holt B, Zweegman S, et al, &ldquo;A Randomized Phase 3 Study on the Effect of Thalidomide Combined With Adriamycin, Dexamethasone, and High-Dose Melphalan, Followed by Thalidomide Maintenance in Patients With Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(6):1113-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/19880501/pubmed\" id=\"19880501\" target=\"_blank\">",
"        19880501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Multiple Myeloma,&rdquo; Version 1.2013. Available at  file://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Onozawa M, Hashino S, Sogabe S, et al, &ldquo;Side Effects and Good Effects from New Chemotherapeutic Agents. Case 2. Thalidomide-Induced Interstitial Pneumonitis,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(10):2425-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/15800335/pubmed\" id=\"15800335\" target=\"_blank\">",
"        15800335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Bringhen S, Liberati AM, et al, \"Oral Melphalan, Prednisone, and Thalidomide in Elderly Patients With Multiple Myeloma: Updated Results of a Randomized Controlled Trial,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(8):3107-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/18505783/pubmed\" id=\"18505783\" target=\"_blank\">",
"        18505783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Bringhen S, Rossi D, et al, &ldquo;Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(34):5101-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/20940200/pubmed\" id=\"20940200\" target=\"_blank\">",
"        20940200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Rajkumar SV, Dimopoulos MA, et al, &ldquo;Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2008, 22(2): 414-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/18094721/pubmed\" id=\"18094721\" target=\"_blank\">",
"        18094721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker PM, Chao N, Nademanee A, et al, &ldquo; Thalidomide as Salvage Therapy for Chronic Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 86(9):3604-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/7579470/pubmed\" id=\"7579470\" target=\"_blank\">",
"        7579470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rajkumar SV, Blood E, Vesole D, et al, &ldquo;Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(3):431-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/16365178/pubmed\" id=\"16365178\" target=\"_blank\">",
"        16365178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Delforge M, Beksac M, et al, &ldquo;Management of Treatment-Emergent Peripheral Neuropathy in Multiple Myeloma,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2012, 26(4):595-608.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/22193964/pubmed\" id=\"22193964\" target=\"_blank\">",
"        22193964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rovelli A, Arrigo C, Nesi F, et al, &ldquo;The Role of Thalidomide in the Treatment of Refractory Chronic Graft-Versus-Host Disease Following Bone Marrow Transplantation in Children,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1998, 21(6):577-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/9543061/pubmed\" id=\"9543061\" target=\"_blank\">",
"        9543061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seol Y, Chung J, Kwon B, et al, &ldquo;Treatment for Patients With Multiple Myeloma Complicated by Renal Failure by Thalidomide-Based Regimens,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(suppl):e13093 [abstract e13093 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spencer A, Prince HM, Roberts AW, et al, &ldquo;Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(11):1788-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/19273705/pubmed\" id=\"19273705\" target=\"_blank\">",
"        19273705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tosi P, Zamagni E, Tacchetti P, et al, &ldquo;Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma and Renal Failure,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(22):4934 [abstract 4934 from 2009 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treon SP, Soumerai JD, Branagan AR, et al, &ldquo;Thalidomide and Rituximab in Waldenstrom Macroglobulinemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(12):4552-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/18713945/pubmed\" id=\"18713945\" target=\"_blank\">",
"        18713945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uhl K, Cox E, Rogan R, et al, &ldquo;Thalidomide Use in the US: Experience With Pregnancy Testing in the S.T.E.P.S.&reg; Programme,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2006, 29(4):231-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/16524322/pubmed\" id=\"16524322\" target=\"_blank\">",
"        16524322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al, &ldquo;An Open-Label Pilot Study of Low-Dose Thalidomide in Chronically Active, Steroid-Dependent Crohn's Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1999, 117(6):1278-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/10579968/pubmed\" id=\"10579968\" target=\"_blank\">",
"        10579968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vogelsang GB, Farmer ER, Hess AD, et al, &ldquo;Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(16):1055-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/1549151/pubmed\" id=\"1549151\" target=\"_blank\">",
"        1549151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wechalekar AD, Goodman HJ, Lachmann HJ, et al, &ldquo;Safety and Efficacy of Risk-Adapted Cyclophosphamide, Thalidomide, and Dexamethasone in Systemic AL Amyloidosis,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(2):457-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/16990593/pubmed\" id=\"16990593\" target=\"_blank\">",
"        16990593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wijermans P, Schaafsma M, Termorshuizen F, et al, &ldquo;Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: the HOVON 49 Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(19):3160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/20516439/pubmed\" id=\"20516439\" target=\"_blank\">",
"        20516439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolff D, Schleuning M, von Harsdorf S, et al, &ldquo;Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2010, 17(1):1-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/62/29673/abstract-text/20685255/pubmed\" id=\"20685255\" target=\"_blank\">",
"        20685255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10095 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29673=[""].join("\n");
var outline_f28_62_29673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708930\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226481\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226482\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226500\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226484\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10927005\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226485\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12926530\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12926531\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10927004\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226457\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226442\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234348\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10523386\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226461\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226460\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226496\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226506\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226498\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226464\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226446\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300130\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226450\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226477\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226452\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226466\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226489\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226467\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226468\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323954\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226454\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226458\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226469\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226445\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226463\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/48/44805?source=related_link\">",
"      Thalidomide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/42/42664?source=related_link\">",
"      Thalidomide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_62_29674="EEG Positive occipital sharp transients of sleep POSTS";
var content_f28_62_29674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Positive occipital sharp transients of sleep (POSTS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 610px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) POSTS (Positive occipital sharp transients of sleep), in runs, in a bipolar montage (red arrows). B) A referential recording confirms the positivity in the occipital regions (downgoing waves; green arrows). These are normal discharges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Lawrence Hirsch and Hiba Arif.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29674=[""].join("\n");
var outline_f28_62_29674=null;
var title_f28_62_29675="Indications and timing of the infertility evaluation";
var content_f28_62_29675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications and timing of the infertility evaluation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infertility evaluation is indicated for couples who seek help because they have not been able to conceive.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       1. Initiate evaluation after 12 months of unprotected and frequent intercourse:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Women under age 35 years without risk factors for infertility.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       2. Initiate evaluation after six months of unprotected and frequent intercourse:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Women age 35 to 40 years.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       3. Initiate evaluation upon presentation despite less than six months of unprotected and frequent intercourse:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Women over 40 years of age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Women with oligomenorrhea/amenorrhea.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Women with a history of chemotherapy, radiation therapy, or advanced stage endometriosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Women with known or suspected uterine/tubal disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Women whose male partner has a history of groin or testicular surgery, adult mumps, impotence or other sexual dysfunction, chemotherapy and/or radiation, or a history of subfertility with another partner.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29675=[""].join("\n");
var outline_f28_62_29675=null;
var title_f28_62_29676="Glasgow coma scale";
var content_f28_62_29676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glasgow coma scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"90%\">",
"     </colgroup>",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Eye opening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Response to verbal command",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Response to pain",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No eye opening",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Best verbal response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oriented",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Confused",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inappropriate words",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Incomprehensible sounds",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No verbal response",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Best motor response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obeys commands",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Localizing response to pain",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Withdrawal response to pain",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion to pain",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension to pain",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        No motor response",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The GCS is scored between 3 and 15, 3 being the worst, and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M). The components of the GCS should be recorded individually; for example, E2V3M4 results in a GCS score of 9. A score of 13 or higher correlates with mild brain injury; a score of 9 to 12 correlates with moderate injury; and a score of 8 or less represents severe brain injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29676=[""].join("\n");
var outline_f28_62_29676=null;
var title_f28_62_29677="ACE inhibitors improve outcome after MI";
var content_f28_62_29677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitors improve outcome after a myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 247px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A meta-analysis of 5966 patients with left ventricular dysfunction after a myocardial infarction enrolled in the SAVE, AIRE, and TRACE trials shows that after a median follow-up of 31 months there is a significant reduction in mortality with an angiotensin converting enzyme (ACE) inhibitor (23.4 versus 29 percent, odds ratio 0.74, p &lt;0.0001). There is a continuing divergence in the mortality curves during follow-up that exceeds four years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Flather MD, Yusuf S, Kober L, et al. Lancet 2000; 355:1575.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29677=[""].join("\n");
var outline_f28_62_29677=null;
var title_f28_62_29678="Small bowel ischemia on plain abdominal film";
var content_f28_62_29678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel ischemia on plain abdominal film",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A plain radiograph of the abdomen demonstrates distended featureless loops of small bowel with wall thickening (arrow) and separation of the bowel loops. These findings are consistent with hemorrhage into the bowel wall secondary to ischemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan B Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29678=[""].join("\n");
var outline_f28_62_29678=null;
var title_f28_62_29679="Cryptogenic organizing pneumonia CXR I";
var content_f28_62_29679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptogenic organizing pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sixty-two year old man with a one month history of dyspnea with exertion, fatigue, and weight loss due to cryptogenic organizing pneumonitis. Posteroanterior roentgenogram reveals bilateral patchy alveolar opacities. There was complete resolution following&nbsp;glucocorticoid therapy. Unfortunately, the disease recurred several times following withdrawal of&nbsp;glucocorticoid therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_62_29679=[""].join("\n");
var outline_f28_62_29679=null;
